WO2024102699A1 - Formulations de stimulateur de guanylate cyclase (gc) et leurs utilisations - Google Patents
Formulations de stimulateur de guanylate cyclase (gc) et leurs utilisations Download PDFInfo
- Publication number
- WO2024102699A1 WO2024102699A1 PCT/US2023/078897 US2023078897W WO2024102699A1 WO 2024102699 A1 WO2024102699 A1 WO 2024102699A1 US 2023078897 W US2023078897 W US 2023078897W WO 2024102699 A1 WO2024102699 A1 WO 2024102699A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- stimulator
- less
- total
- months
- pharmaceutical formulation
- Prior art date
Links
- 108010078321 Guanylate Cyclase Proteins 0.000 title claims abstract description 282
- 102000014469 Guanylate cyclase Human genes 0.000 title claims abstract description 282
- 239000000203 mixture Substances 0.000 title claims abstract description 95
- 238000009472 formulation Methods 0.000 title abstract description 70
- 229940100692 oral suspension Drugs 0.000 claims abstract description 105
- 238000000034 method Methods 0.000 claims abstract description 93
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 49
- 201000010099 disease Diseases 0.000 claims abstract description 48
- 206010020772 Hypertension Diseases 0.000 claims abstract description 45
- 239000008194 pharmaceutical composition Substances 0.000 claims description 80
- 239000007787 solid Substances 0.000 claims description 73
- 239000004094 surface-active agent Substances 0.000 claims description 60
- 239000000872 buffer Substances 0.000 claims description 49
- 239000003755 preservative agent Substances 0.000 claims description 43
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 42
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 39
- 230000015556 catabolic process Effects 0.000 claims description 34
- 238000006731 degradation reaction Methods 0.000 claims description 34
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 33
- 239000002253 acid Substances 0.000 claims description 32
- 239000003112 inhibitor Substances 0.000 claims description 31
- 230000002335 preservative effect Effects 0.000 claims description 31
- 239000000654 additive Substances 0.000 claims description 30
- 230000000996 additive effect Effects 0.000 claims description 30
- 150000001875 compounds Chemical class 0.000 claims description 30
- 239000003814 drug Substances 0.000 claims description 30
- 239000000796 flavoring agent Substances 0.000 claims description 30
- 235000013355 food flavoring agent Nutrition 0.000 claims description 30
- 239000008363 phosphate buffer Substances 0.000 claims description 30
- 239000002562 thickening agent Substances 0.000 claims description 30
- 238000009736 wetting Methods 0.000 claims description 30
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 28
- 230000036470 plasma concentration Effects 0.000 claims description 28
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 27
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 27
- 230000036772 blood pressure Effects 0.000 claims description 27
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 claims description 27
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 claims description 27
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 27
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 27
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 27
- 239000000243 solution Substances 0.000 claims description 27
- 230000035488 systolic blood pressure Effects 0.000 claims description 26
- 239000005557 antagonist Substances 0.000 claims description 23
- 230000004872 arterial blood pressure Effects 0.000 claims description 23
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 23
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 22
- 229940124597 therapeutic agent Drugs 0.000 claims description 21
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 21
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims description 20
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 20
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 20
- 229940095259 butylated hydroxytoluene Drugs 0.000 claims description 20
- 238000010979 pH adjustment Methods 0.000 claims description 20
- 230000005855 radiation Effects 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 20
- 230000035487 diastolic blood pressure Effects 0.000 claims description 19
- 230000003247 decreasing effect Effects 0.000 claims description 16
- 238000001990 intravenous administration Methods 0.000 claims description 16
- 241000894007 species Species 0.000 claims description 16
- 238000001195 ultra high performance liquid chromatography Methods 0.000 claims description 16
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 15
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 15
- 208000001871 Tachycardia Diseases 0.000 claims description 14
- 229940061607 dibasic sodium phosphate Drugs 0.000 claims description 14
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 13
- 229960004106 citric acid Drugs 0.000 claims description 13
- 229920001577 copolymer Polymers 0.000 claims description 13
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 12
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 12
- 229960002216 methylparaben Drugs 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 claims description 11
- 229960002303 citric acid monohydrate Drugs 0.000 claims description 11
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 11
- 230000007062 hydrolysis Effects 0.000 claims description 11
- 238000006460 hydrolysis reaction Methods 0.000 claims description 11
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 11
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 11
- 229960003415 propylparaben Drugs 0.000 claims description 11
- 229940075582 sorbic acid Drugs 0.000 claims description 11
- 235000010199 sorbic acid Nutrition 0.000 claims description 11
- 239000004334 sorbic acid Substances 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 11
- 230000006794 tachycardia Effects 0.000 claims description 11
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims description 10
- 241000251468 Actinopterygii Species 0.000 claims description 10
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims description 10
- 206010003671 Atrioventricular Block Diseases 0.000 claims description 10
- 241000282465 Canis Species 0.000 claims description 10
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 10
- 241000283073 Equus caballus Species 0.000 claims description 10
- 241000282324 Felis Species 0.000 claims description 10
- 241000287828 Gallus gallus Species 0.000 claims description 10
- 241000578500 Ninox novaeseelandiae Species 0.000 claims description 10
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 claims description 10
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 claims description 10
- 239000007983 Tris buffer Substances 0.000 claims description 10
- 235000009499 Vanilla fragrans Nutrition 0.000 claims description 10
- 244000263375 Vanilla tahitensis Species 0.000 claims description 10
- 235000012036 Vanilla tahitensis Nutrition 0.000 claims description 10
- 208000009729 Ventricular Premature Complexes Diseases 0.000 claims description 10
- 239000013543 active substance Substances 0.000 claims description 10
- 239000003146 anticoagulant agent Substances 0.000 claims description 10
- 230000001746 atrial effect Effects 0.000 claims description 10
- 235000015278 beef Nutrition 0.000 claims description 10
- 239000003613 bile acid Substances 0.000 claims description 10
- 235000013351 cheese Nutrition 0.000 claims description 10
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 claims description 10
- ZOOGRGPOEVQQDX-KHLHZJAASA-N cyclic guanosine monophosphate Chemical compound C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 claims description 10
- BYNVYIUJKRRNNC-UHFFFAOYSA-N docosanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCCCCCC(O)=O BYNVYIUJKRRNNC-UHFFFAOYSA-N 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims description 10
- -1 quinopril Chemical compound 0.000 claims description 10
- 229960001148 rivaroxaban Drugs 0.000 claims description 10
- KGFYHTZWPPHNLQ-AWEZNQCLSA-N rivaroxaban Chemical compound S1C(Cl)=CC=C1C(=O)NC[C@@H]1OC(=O)N(C=2C=CC(=CC=2)N2C(COCC2)=O)C1 KGFYHTZWPPHNLQ-AWEZNQCLSA-N 0.000 claims description 10
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 claims description 10
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 claims description 10
- 239000003125 aqueous solvent Substances 0.000 claims description 9
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 9
- 239000000556 agonist Substances 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 230000000747 cardiac effect Effects 0.000 claims description 6
- 229960002768 dipyridamole Drugs 0.000 claims description 6
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 claims description 6
- 230000004060 metabolic process Effects 0.000 claims description 6
- 238000003786 synthesis reaction Methods 0.000 claims description 6
- CEMAWMOMDPGJMB-UHFFFAOYSA-N (+-)-Oxprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1OCC=C CEMAWMOMDPGJMB-UHFFFAOYSA-N 0.000 claims description 5
- NXWGWUVGUSFQJC-GFCCVEGCSA-N (2r)-1-[(2-methyl-1h-indol-4-yl)oxy]-3-(propan-2-ylamino)propan-2-ol Chemical compound CC(C)NC[C@@H](O)COC1=CC=CC2=C1C=C(C)N2 NXWGWUVGUSFQJC-GFCCVEGCSA-N 0.000 claims description 5
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 claims description 5
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 5
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 claims description 5
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 claims description 5
- KOHIRBRYDXPAMZ-YHBROIRLSA-N (S,R,R,R)-nebivolol Chemical compound C1CC2=CC(F)=CC=C2O[C@H]1[C@H](O)CNC[C@@H](O)[C@H]1OC2=CC=C(F)C=C2CC1 KOHIRBRYDXPAMZ-YHBROIRLSA-N 0.000 claims description 5
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 claims description 5
- OFJRNBWSFXEHSA-UHFFFAOYSA-N 2-(3-amino-1,2-benzoxazol-5-yl)-n-[4-[2-[(dimethylamino)methyl]imidazol-1-yl]-2-fluorophenyl]-5-(trifluoromethyl)pyrazole-3-carboxamide Chemical compound CN(C)CC1=NC=CN1C(C=C1F)=CC=C1NC(=O)C1=CC(C(F)(F)F)=NN1C1=CC=C(ON=C2N)C2=C1 OFJRNBWSFXEHSA-UHFFFAOYSA-N 0.000 claims description 5
- FBMYKMYQHCBIGU-UHFFFAOYSA-N 2-[2-hydroxy-3-[[1-(1h-indol-3-yl)-2-methylpropan-2-yl]amino]propoxy]benzonitrile Chemical compound C=1NC2=CC=CC=C2C=1CC(C)(C)NCC(O)COC1=CC=CC=C1C#N FBMYKMYQHCBIGU-UHFFFAOYSA-N 0.000 claims description 5
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 claims description 5
- NCGICGYLBXGBGN-UHFFFAOYSA-N 3-morpholin-4-yl-1-oxa-3-azonia-2-azanidacyclopent-3-en-5-imine;hydrochloride Chemical compound Cl.[N-]1OC(=N)C=[N+]1N1CCOCC1 NCGICGYLBXGBGN-UHFFFAOYSA-N 0.000 claims description 5
- 239000005541 ACE inhibitor Substances 0.000 claims description 5
- 206010002199 Anaphylactic shock Diseases 0.000 claims description 5
- 206010002329 Aneurysm Diseases 0.000 claims description 5
- 206010002383 Angina Pectoris Diseases 0.000 claims description 5
- 102000015427 Angiotensins Human genes 0.000 claims description 5
- 108010064733 Angiotensins Proteins 0.000 claims description 5
- 206010002921 Aortitis Diseases 0.000 claims description 5
- QNZCBYKSOIHPEH-UHFFFAOYSA-N Apixaban Chemical compound C1=CC(OC)=CC=C1N1C(C(=O)N(CC2)C=3C=CC(=CC=3)N3C(CCCC3)=O)=C2C(C(N)=O)=N1 QNZCBYKSOIHPEH-UHFFFAOYSA-N 0.000 claims description 5
- 206010003130 Arrhythmia supraventricular Diseases 0.000 claims description 5
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 5
- 206010003658 Atrial Fibrillation Diseases 0.000 claims description 5
- 208000002102 Atrial Premature Complexes Diseases 0.000 claims description 5
- 206010003662 Atrial flutter Diseases 0.000 claims description 5
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 claims description 5
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 claims description 5
- 239000002083 C09CA01 - Losartan Substances 0.000 claims description 5
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims description 5
- 239000002053 C09CA06 - Candesartan Substances 0.000 claims description 5
- 239000005537 C09CA07 - Telmisartan Substances 0.000 claims description 5
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 5
- 206010007556 Cardiac failure acute Diseases 0.000 claims description 5
- 206010007558 Cardiac failure chronic Diseases 0.000 claims description 5
- JOATXPAWOHTVSZ-UHFFFAOYSA-N Celiprolol Chemical compound CCN(CC)C(=O)NC1=CC=C(OCC(O)CNC(C)(C)C)C(C(C)=O)=C1 JOATXPAWOHTVSZ-UHFFFAOYSA-N 0.000 claims description 5
- 229940127328 Cholesterol Synthesis Inhibitors Drugs 0.000 claims description 5
- 108010061435 Enalapril Proteins 0.000 claims description 5
- 102000002045 Endothelin Human genes 0.000 claims description 5
- 108050009340 Endothelin Proteins 0.000 claims description 5
- YARKMNAWFIMDKV-UHFFFAOYSA-N Epanolol Chemical compound C=1C=CC=C(C#N)C=1OCC(O)CNCCNC(=O)CC1=CC=C(O)C=C1 YARKMNAWFIMDKV-UHFFFAOYSA-N 0.000 claims description 5
- 206010015856 Extrasystoles Diseases 0.000 claims description 5
- 229940123583 Factor Xa inhibitor Drugs 0.000 claims description 5
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 claims description 5
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 claims description 5
- 102100025306 Integrin alpha-IIb Human genes 0.000 claims description 5
- 101710149643 Integrin alpha-IIb Proteins 0.000 claims description 5
- 229940127470 Lipase Inhibitors Drugs 0.000 claims description 5
- 102000057248 Lipoprotein(a) Human genes 0.000 claims description 5
- 108010033266 Lipoprotein(a) Proteins 0.000 claims description 5
- 108010007859 Lisinopril Proteins 0.000 claims description 5
- 229910002651 NO3 Inorganic materials 0.000 claims description 5
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 5
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 claims description 5
- 239000000006 Nitroglycerin Substances 0.000 claims description 5
- 108010016731 PPAR gamma Proteins 0.000 claims description 5
- 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 claims description 5
- 102100038824 Peroxisome proliferator-activated receptor delta Human genes 0.000 claims description 5
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 claims description 5
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 claims description 5
- 208000000418 Premature Cardiac Complexes Diseases 0.000 claims description 5
- 206010040070 Septic Shock Diseases 0.000 claims description 5
- 206010040639 Sick sinus syndrome Diseases 0.000 claims description 5
- 208000007718 Stable Angina Diseases 0.000 claims description 5
- 206010065342 Supraventricular tachyarrhythmia Diseases 0.000 claims description 5
- 241000134128 Syncope Species 0.000 claims description 5
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 5
- 229940122388 Thrombin inhibitor Drugs 0.000 claims description 5
- 208000018452 Torsade de pointes Diseases 0.000 claims description 5
- 208000002363 Torsades de Pointes Diseases 0.000 claims description 5
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 claims description 5
- 208000007814 Unstable Angina Diseases 0.000 claims description 5
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 claims description 5
- 208000008131 Ventricular Flutter Diseases 0.000 claims description 5
- 206010047281 Ventricular arrhythmia Diseases 0.000 claims description 5
- 206010047289 Ventricular extrasystoles Diseases 0.000 claims description 5
- 206010065341 Ventricular tachyarrhythmia Diseases 0.000 claims description 5
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 5
- 201000008803 Wolff-Parkinson-white syndrome Diseases 0.000 claims description 5
- 229960000446 abciximab Drugs 0.000 claims description 5
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 5
- 230000001154 acute effect Effects 0.000 claims description 5
- 229950000221 adaprolol Drugs 0.000 claims description 5
- IPGLIOFIFLXLKR-AXYNENQYSA-N adaprolol Chemical compound C1=CC(OCC(O)CNC(C)C)=CC=C1CC(=O)OCCC1(C2)C[C@@H](C3)C[C@H]2C[C@@H]3C1 IPGLIOFIFLXLKR-AXYNENQYSA-N 0.000 claims description 5
- 229940083712 aldosterone antagonist Drugs 0.000 claims description 5
- 239000002160 alpha blocker Substances 0.000 claims description 5
- 229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 claims description 5
- 229960002213 alprenolol Drugs 0.000 claims description 5
- PAZJSJFMUHDSTF-UHFFFAOYSA-N alprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1CC=C PAZJSJFMUHDSTF-UHFFFAOYSA-N 0.000 claims description 5
- 229960002414 ambrisentan Drugs 0.000 claims description 5
- OUJTZYPIHDYQMC-LJQANCHMSA-N ambrisentan Chemical compound O([C@@H](C(OC)(C=1C=CC=CC=1)C=1C=CC=CC=1)C(O)=O)C1=NC(C)=CC(C)=N1 OUJTZYPIHDYQMC-LJQANCHMSA-N 0.000 claims description 5
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 claims description 5
- 229960000528 amlodipine Drugs 0.000 claims description 5
- 208000003455 anaphylaxis Diseases 0.000 claims description 5
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 5
- 229940127219 anticoagulant drug Drugs 0.000 claims description 5
- 229940127218 antiplatelet drug Drugs 0.000 claims description 5
- 229960004676 antithrombotic agent Drugs 0.000 claims description 5
- 239000003698 antivitamin K Substances 0.000 claims description 5
- 229960003886 apixaban Drugs 0.000 claims description 5
- 206010003119 arrhythmia Diseases 0.000 claims description 5
- 230000006793 arrhythmia Effects 0.000 claims description 5
- 229960002274 atenolol Drugs 0.000 claims description 5
- 230000001363 autoimmune Effects 0.000 claims description 5
- 239000002876 beta blocker Substances 0.000 claims description 5
- 229940097320 beta blocking agent Drugs 0.000 claims description 5
- 229960004324 betaxolol Drugs 0.000 claims description 5
- CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 claims description 5
- 229960002781 bisoprolol Drugs 0.000 claims description 5
- VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 claims description 5
- 229960003065 bosentan Drugs 0.000 claims description 5
- GJPICJJJRGTNOD-UHFFFAOYSA-N bosentan Chemical compound COC1=CC=CC=C1OC(C(=NC(=N1)C=2N=CC=CN=2)OCCO)=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 GJPICJJJRGTNOD-UHFFFAOYSA-N 0.000 claims description 5
- 229950005341 bucindolol Drugs 0.000 claims description 5
- 229960000330 bupranolol Drugs 0.000 claims description 5
- HQIRNZOQPUAHHV-UHFFFAOYSA-N bupranolol Chemical compound CC1=CC=C(Cl)C(OCC(O)CNC(C)(C)C)=C1 HQIRNZOQPUAHHV-UHFFFAOYSA-N 0.000 claims description 5
- 229960000932 candesartan Drugs 0.000 claims description 5
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 claims description 5
- 229960000830 captopril Drugs 0.000 claims description 5
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims description 5
- BQXQGZPYHWWCEB-UHFFFAOYSA-N carazolol Chemical compound N1C2=CC=CC=C2C2=C1C=CC=C2OCC(O)CNC(C)C BQXQGZPYHWWCEB-UHFFFAOYSA-N 0.000 claims description 5
- 229960004634 carazolol Drugs 0.000 claims description 5
- 206010007625 cardiogenic shock Diseases 0.000 claims description 5
- 229960001222 carteolol Drugs 0.000 claims description 5
- LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 claims description 5
- 229960004195 carvedilol Drugs 0.000 claims description 5
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 claims description 5
- 229960002320 celiprolol Drugs 0.000 claims description 5
- 230000001906 cholesterol absorption Effects 0.000 claims description 5
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 claims description 5
- 229960003009 clopidogrel Drugs 0.000 claims description 5
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 claims description 5
- 208000029078 coronary artery disease Diseases 0.000 claims description 5
- 229960000956 coumarin Drugs 0.000 claims description 5
- 235000001671 coumarin Nutrition 0.000 claims description 5
- 229960003850 dabigatran Drugs 0.000 claims description 5
- YBSJFWOBGCMAKL-UHFFFAOYSA-N dabigatran Chemical compound N=1C2=CC(C(=O)N(CCC(O)=O)C=3N=CC=CC=3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 YBSJFWOBGCMAKL-UHFFFAOYSA-N 0.000 claims description 5
- FEJVSJIALLTFRP-LJQANCHMSA-N darusentan Chemical compound COC1=CC(OC)=NC(O[C@H](C(O)=O)C(OC)(C=2C=CC=CC=2)C=2C=CC=CC=2)=N1 FEJVSJIALLTFRP-LJQANCHMSA-N 0.000 claims description 5
- 229950008833 darusentan Drugs 0.000 claims description 5
- 229960005227 delapril Drugs 0.000 claims description 5
- WOUOLAUOZXOLJQ-MBSDFSHPSA-N delapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=CC=CC=C2C1)CC1=CC=CC=C1 WOUOLAUOZXOLJQ-MBSDFSHPSA-N 0.000 claims description 5
- 229960004166 diltiazem Drugs 0.000 claims description 5
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 claims description 5
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 claims description 5
- 239000002934 diuretic Substances 0.000 claims description 5
- 229940030606 diuretics Drugs 0.000 claims description 5
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 5
- 229960000873 enalapril Drugs 0.000 claims description 5
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims description 5
- 206010014665 endocarditis Diseases 0.000 claims description 5
- 239000002308 endothelin receptor antagonist Substances 0.000 claims description 5
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 claims description 5
- 229960002711 epanolol Drugs 0.000 claims description 5
- 229960003745 esmolol Drugs 0.000 claims description 5
- AQNDDEOPVVGCPG-UHFFFAOYSA-N esmolol Chemical compound COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1 AQNDDEOPVVGCPG-UHFFFAOYSA-N 0.000 claims description 5
- 229950010034 fidexaban Drugs 0.000 claims description 5
- 229960001318 fondaparinux Drugs 0.000 claims description 5
- KANJSNBRCNMZMV-ABRZTLGGSA-N fondaparinux Chemical compound O[C@@H]1[C@@H](NS(O)(=O)=O)[C@@H](OC)O[C@H](COS(O)(=O)=O)[C@H]1O[C@H]1[C@H](OS(O)(=O)=O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O4)NS(O)(=O)=O)[C@H](O3)C(O)=O)O)[C@@H](COS(O)(=O)=O)O2)NS(O)(=O)=O)[C@H](C(O)=O)O1 KANJSNBRCNMZMV-ABRZTLGGSA-N 0.000 claims description 5
- 229960002490 fosinopril Drugs 0.000 claims description 5
- 229960003711 glyceryl trinitrate Drugs 0.000 claims description 5
- 208000019622 heart disease Diseases 0.000 claims description 5
- 229960002897 heparin Drugs 0.000 claims description 5
- 229920000669 heparin Polymers 0.000 claims description 5
- 239000002628 heparin derivative Substances 0.000 claims description 5
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 claims description 5
- 229960000201 isosorbide dinitrate Drugs 0.000 claims description 5
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 claims description 5
- 229960003827 isosorbide mononitrate Drugs 0.000 claims description 5
- 229960001632 labetalol Drugs 0.000 claims description 5
- 229950005241 landiolol Drugs 0.000 claims description 5
- WMDSZGFJQKSLLH-RBBKRZOGSA-N landiolol Chemical compound O1C(C)(C)OC[C@H]1COC(=O)CCC(C=C1)=CC=C1OC[C@@H](O)CNCCNC(=O)N1CCOCC1 WMDSZGFJQKSLLH-RBBKRZOGSA-N 0.000 claims description 5
- 229960002394 lisinopril Drugs 0.000 claims description 5
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 claims description 5
- 229960004773 losartan Drugs 0.000 claims description 5
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 claims description 5
- DKWNMCUOEDMMIN-PKOBYXMFSA-N melagatran Chemical compound C1=CC(C(=N)N)=CC=C1CNC(=O)[C@H]1N(C(=O)[C@H](NCC(O)=O)C2CCCCC2)CC1 DKWNMCUOEDMMIN-PKOBYXMFSA-N 0.000 claims description 5
- 229960002137 melagatran Drugs 0.000 claims description 5
- 229960003134 mepindolol Drugs 0.000 claims description 5
- 229960002704 metipranolol Drugs 0.000 claims description 5
- BLWNYSZZZWQCKO-UHFFFAOYSA-N metipranolol hydrochloride Chemical compound [Cl-].CC(C)[NH2+]CC(O)COC1=CC(C)=C(OC(C)=O)C(C)=C1C BLWNYSZZZWQCKO-UHFFFAOYSA-N 0.000 claims description 5
- 229960002237 metoprolol Drugs 0.000 claims description 5
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 claims description 5
- 239000002394 mineralocorticoid antagonist Substances 0.000 claims description 5
- XLFWDASMENKTKL-UHFFFAOYSA-N molsidomine Chemical compound O1C(N=C([O-])OCC)=C[N+](N2CCOCC2)=N1 XLFWDASMENKTKL-UHFFFAOYSA-N 0.000 claims description 5
- 229960004027 molsidomine Drugs 0.000 claims description 5
- 229960004255 nadolol Drugs 0.000 claims description 5
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 claims description 5
- 229960000619 nebivolol Drugs 0.000 claims description 5
- 229960001597 nifedipine Drugs 0.000 claims description 5
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims description 5
- 239000002840 nitric oxide donor Substances 0.000 claims description 5
- MVPQUSQUURLQKF-MCPDASDXSA-E nonasodium;(2s,3s,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3s,4s,5r,6r)-2-carboxylato-4,5-dimethoxy-6-[(2r,3r,4s,5r,6s)-6-methoxy-4,5-disulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-disulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl]oxy-4,5-di Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[O-]S(=O)(=O)O[C@@H]1[C@@H](OS([O-])(=O)=O)[C@@H](OC)O[C@H](COS([O-])(=O)=O)[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@@H]2[C@@H]([C@@H](OS([O-])(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](OC)[C@H](O[C@@H]4[C@@H]([C@@H](OC)[C@H](OC)[C@@H](COS([O-])(=O)=O)O4)OC)[C@H](O3)C([O-])=O)OC)[C@@H](COS([O-])(=O)=O)O2)OS([O-])(=O)=O)[C@H](C([O-])=O)O1 MVPQUSQUURLQKF-MCPDASDXSA-E 0.000 claims description 5
- 229940100688 oral solution Drugs 0.000 claims description 5
- 229950009478 otamixaban Drugs 0.000 claims description 5
- PFGVNLZDWRZPJW-OPAMFIHVSA-N otamixaban Chemical compound C([C@@H](C(=O)OC)[C@@H](C)NC(=O)C=1C=CC(=CC=1)C=1C=C[N+]([O-])=CC=1)C1=CC=CC(C(N)=N)=C1 PFGVNLZDWRZPJW-OPAMFIHVSA-N 0.000 claims description 5
- 229960004570 oxprenolol Drugs 0.000 claims description 5
- 238000007911 parenteral administration Methods 0.000 claims description 5
- 229960002035 penbutolol Drugs 0.000 claims description 5
- KQXKVJAGOJTNJS-HNNXBMFYSA-N penbutolol Chemical compound CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1 KQXKVJAGOJTNJS-HNNXBMFYSA-N 0.000 claims description 5
- 208000008494 pericarditis Diseases 0.000 claims description 5
- 229960002582 perindopril Drugs 0.000 claims description 5
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 claims description 5
- 230000002093 peripheral effect Effects 0.000 claims description 5
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 claims description 5
- 108091008765 peroxisome proliferator-activated receptors β/δ Proteins 0.000 claims description 5
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 claims description 5
- 229960002508 pindolol Drugs 0.000 claims description 5
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 claims description 5
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims description 5
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 claims description 5
- 229960001289 prazosin Drugs 0.000 claims description 5
- 229960003712 propranolol Drugs 0.000 claims description 5
- 229960003401 ramipril Drugs 0.000 claims description 5
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 claims description 5
- 229950010535 razaxaban Drugs 0.000 claims description 5
- 230000009103 reabsorption Effects 0.000 claims description 5
- 239000000018 receptor agonist Substances 0.000 claims description 5
- 229940044601 receptor agonist Drugs 0.000 claims description 5
- 239000003087 receptor blocking agent Substances 0.000 claims description 5
- 239000002461 renin inhibitor Substances 0.000 claims description 5
- 229940086526 renin-inhibitors Drugs 0.000 claims description 5
- 208000015658 resistant hypertension Diseases 0.000 claims description 5
- 230000036303 septic shock Effects 0.000 claims description 5
- 230000035939 shock Effects 0.000 claims description 5
- 229960003310 sildenafil Drugs 0.000 claims description 5
- 229960002578 sitaxentan Drugs 0.000 claims description 5
- PHWXUGHIIBDVKD-UHFFFAOYSA-N sitaxentan Chemical compound CC1=NOC(NS(=O)(=O)C2=C(SC=C2)C(=O)CC=2C(=CC=3OCOC=3C=2)C)=C1Cl PHWXUGHIIBDVKD-UHFFFAOYSA-N 0.000 claims description 5
- 229940083618 sodium nitroprusside Drugs 0.000 claims description 5
- 229960002370 sotalol Drugs 0.000 claims description 5
- ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 claims description 5
- 229940031439 squalene Drugs 0.000 claims description 5
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 5
- 206010042772 syncope Diseases 0.000 claims description 5
- 229960000835 tadalafil Drugs 0.000 claims description 5
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 claims description 5
- 229960005187 telmisartan Drugs 0.000 claims description 5
- 239000003868 thrombin inhibitor Substances 0.000 claims description 5
- 102000004217 thyroid hormone receptors Human genes 0.000 claims description 5
- 108090000721 thyroid hormone receptors Proteins 0.000 claims description 5
- 229960005001 ticlopidine Drugs 0.000 claims description 5
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 claims description 5
- 229960004605 timolol Drugs 0.000 claims description 5
- 229960003425 tirofiban Drugs 0.000 claims description 5
- COKMIXFXJJXBQG-NRFANRHFSA-N tirofiban Chemical compound C1=CC(C[C@H](NS(=O)(=O)CCCC)C(O)=O)=CC=C1OCCCCC1CCNCC1 COKMIXFXJJXBQG-NRFANRHFSA-N 0.000 claims description 5
- 230000000699 topical effect Effects 0.000 claims description 5
- 229940126702 topical medication Drugs 0.000 claims description 5
- 229960004699 valsartan Drugs 0.000 claims description 5
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims description 5
- 229960002381 vardenafil Drugs 0.000 claims description 5
- 208000019553 vascular disease Diseases 0.000 claims description 5
- 208000003663 ventricular fibrillation Diseases 0.000 claims description 5
- 206010047302 ventricular tachycardia Diseases 0.000 claims description 5
- 229960001722 verapamil Drugs 0.000 claims description 5
- 229940019333 vitamin k antagonists Drugs 0.000 claims description 5
- ZXIBCJHYVWYIKI-PZJWPPBQSA-N ximelagatran Chemical compound C1([C@@H](NCC(=O)OCC)C(=O)N2[C@@H](CC2)C(=O)NCC=2C=CC(=CC=2)C(\N)=N\O)CCCCC1 ZXIBCJHYVWYIKI-PZJWPPBQSA-N 0.000 claims description 5
- 229960001522 ximelagatran Drugs 0.000 claims description 5
- OIRCOABEOLEUMC-GEJPAHFPSA-N bivalirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 claims description 4
- 229960001500 bivalirudin Drugs 0.000 claims description 4
- 108010055460 bivalirudin Proteins 0.000 claims description 4
- 230000000019 pro-fibrinolytic effect Effects 0.000 claims description 4
- 210000001992 atrioventricular node Anatomy 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- NPNSVNGQJGRSNR-UHFFFAOYSA-N chembl73193 Chemical compound N=1C(OC=2C(=CC=C(C=2)C(N)=N)O)=C(F)C(N(CC(O)=O)C)=C(F)C=1OC(C=1)=CC=CC=1C1=NCCN1C NPNSVNGQJGRSNR-UHFFFAOYSA-N 0.000 claims 2
- 241000282326 Felis catus Species 0.000 description 59
- 238000011282 treatment Methods 0.000 description 39
- 241000700159 Rattus Species 0.000 description 38
- 230000000694 effects Effects 0.000 description 26
- 241001465754 Metazoa Species 0.000 description 25
- 239000000725 suspension Substances 0.000 description 23
- 230000007423 decrease Effects 0.000 description 21
- 238000012360 testing method Methods 0.000 description 17
- 238000000338 in vitro Methods 0.000 description 16
- 241000282472 Canis lupus familiaris Species 0.000 description 15
- 230000000052 comparative effect Effects 0.000 description 12
- 230000037396 body weight Effects 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 229940068196 placebo Drugs 0.000 description 10
- 239000000902 placebo Substances 0.000 description 10
- 210000002381 plasma Anatomy 0.000 description 10
- 230000002265 prevention Effects 0.000 description 10
- 239000003981 vehicle Substances 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 9
- 235000019629 palatability Nutrition 0.000 description 9
- 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 description 8
- 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 description 8
- 108010017384 Blood Proteins Proteins 0.000 description 7
- 102000004506 Blood Proteins Human genes 0.000 description 7
- 231100000673 dose–response relationship Toxicity 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 238000002203 pretreatment Methods 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 230000005923 long-lasting effect Effects 0.000 description 6
- 231100000062 no-observed-adverse-effect level Toxicity 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 241000282693 Cercopithecidae Species 0.000 description 5
- 238000011887 Necropsy Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 230000036760 body temperature Effects 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 230000001631 hypertensive effect Effects 0.000 description 5
- 238000011835 investigation Methods 0.000 description 5
- 231100000607 toxicokinetics Toxicity 0.000 description 5
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 4
- 241000700157 Rattus norvegicus Species 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 4
- 230000036983 biotransformation Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000029142 excretion Effects 0.000 description 4
- 230000000004 hemodynamic effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 230000035699 permeability Effects 0.000 description 4
- 230000009325 pulmonary function Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000011277 treatment modality Methods 0.000 description 4
- QHVBWSIFLCIXBD-UHFFFAOYSA-N 2-[[2-[3-(diaminomethylidene)-6-oxocyclohexa-1,4-dien-1-yl]oxy-3,5-difluoro-6-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]pyridin-4-yl]-methylamino]acetic acid Chemical compound N=1C(OC=2C=C(C=CC=2)C=2N(CCN=2)C)=C(F)C(N(CC(O)=O)C)=C(F)C=1OC1=CC(=C(N)N)C=CC1=O QHVBWSIFLCIXBD-UHFFFAOYSA-N 0.000 description 3
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 3
- 238000009530 blood pressure measurement Methods 0.000 description 3
- 235000015165 citric acid Nutrition 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 229940117927 ethylene oxide Drugs 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 230000006742 locomotor activity Effects 0.000 description 3
- 231100000682 maximum tolerated dose Toxicity 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 238000002577 ophthalmoscopy Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 229940127296 soluble guanylate cyclase stimulator Drugs 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 3
- 238000002411 thermogravimetry Methods 0.000 description 3
- 238000002562 urinalysis Methods 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 230000002747 voluntary effect Effects 0.000 description 3
- LZMHWZHOZLVYDL-UHFFFAOYSA-N 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one Chemical compound C1=CC=C2N3C(=O)ON=C3C=NC2=C1 LZMHWZHOZLVYDL-UHFFFAOYSA-N 0.000 description 2
- 102100022595 Broad substrate specificity ATP-binding cassette transporter ABCG2 Human genes 0.000 description 2
- 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 description 2
- 102100026533 Cytochrome P450 1A2 Human genes 0.000 description 2
- 102100039205 Cytochrome P450 3A4 Human genes 0.000 description 2
- 231100000491 EC50 Toxicity 0.000 description 2
- 101000823298 Homo sapiens Broad substrate specificity ATP-binding cassette transporter ABCG2 Proteins 0.000 description 2
- 101100298362 Homo sapiens PPIG gene Proteins 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000009102 absorption Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000005429 filling process Methods 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000030136 gastric emptying Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 102000056262 human PPIG Human genes 0.000 description 2
- 230000033444 hydroxylation Effects 0.000 description 2
- 238000005805 hydroxylation reaction Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000001853 liver microsome Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 210000001589 microsome Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 230000003617 peroxidasic effect Effects 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 210000004623 platelet-rich plasma Anatomy 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000011886 postmortem examination Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000002287 radioligand Substances 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 231100000057 systemic toxicity Toxicity 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000583 toxicological profile Toxicity 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- ZALGIKFVXKTKPU-UHFFFAOYSA-N (2,2-diethylhydrazinyl) nitrite Chemical compound CCN(CC)NON=O ZALGIKFVXKTKPU-UHFFFAOYSA-N 0.000 description 1
- HAGOWCONESKMDW-FRSCJGFNSA-N (2s)-4-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-4-oxobutanoic acid Chemical compound NC(N)=NCCC[C@@H](C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CC1=CC=CC=C1 HAGOWCONESKMDW-FRSCJGFNSA-N 0.000 description 1
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
- FOSISNXVGQBIAP-ALCCZGGFSA-N (Z)-diethylamino-hydroxyimino-oxidoazanium Chemical compound CCN(CC)[N+](\[O-])=N\O FOSISNXVGQBIAP-ALCCZGGFSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical group OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108010074918 Cytochrome P-450 CYP1A1 Proteins 0.000 description 1
- 108010000561 Cytochrome P-450 CYP2C8 Proteins 0.000 description 1
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 1
- 102100031476 Cytochrome P450 1A1 Human genes 0.000 description 1
- 102100029359 Cytochrome P450 2C8 Human genes 0.000 description 1
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 description 1
- 102100039208 Cytochrome P450 3A5 Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000006558 Dental Calculus Diseases 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010049438 General physical health deterioration Diseases 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 231100000261 OECD 432 In Vitro 3T3 NRU Phototoxicity Test Toxicity 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010043087 Tachyphylaxis Diseases 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000005030 aluminium foil Substances 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 231100000010 clastogenicity Toxicity 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 238000006264 debenzylation reaction Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 125000006287 difluorobenzyl group Chemical group 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000011833 dog model Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000008406 drug-drug interaction Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 210000001752 female genitalia Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 231100000024 genotoxic Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000003119 guanylate cyclase activator Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 210000000260 male genitalia Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 238000007884 metabolite profiling Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000006151 minimal media Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- OPWZJNXEBYOZBW-UHFFFAOYSA-N n-(2-amino-5,5,5-trifluoro-2-methylpentyl)-8-[(2,6-difluorophenyl)methoxy]-2,6-dimethylimidazo[1,2-a]pyridine-3-carboxamide Chemical compound C=1C(C)=CN2C(C(=O)NCC(C)(N)CCC(F)(F)F)=C(C)N=C2C=1OCC1=C(F)C=CC=C1F OPWZJNXEBYOZBW-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000804 nongenotoxic Toxicity 0.000 description 1
- 231100001183 nonphototoxic Toxicity 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000004783 oxidative metabolism Effects 0.000 description 1
- 210000003540 papillary muscle Anatomy 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 231100000242 photoirritation Toxicity 0.000 description 1
- 231100000119 phototoxicity / photoirritation testing Toxicity 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 231100000272 reduced body weight Toxicity 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000036391 respiratory frequency Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000012430 stability testing Methods 0.000 description 1
- 208000023516 stroke disease Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 108010063955 thrombin receptor peptide (42-47) Proteins 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000155 toxicity by organ Toxicity 0.000 description 1
- 230000007675 toxicity by organ Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 239000008371 vanilla flavor Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 230000001196 vasorelaxation Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
Definitions
- the present disclosure relates to formulations for treating hypertension and/or associated diseases. More specifically, the present disclosure relates to formulations comprising a therapeutically effective amount of a guanylate cyclase (GC) stimulator of Formula (I): or a pharmaceutically acceptable salt thereof.
- GC guanylate cyclase
- Hypertension refers to a condition where the blood pressure (the force of the blood pushing against the artery walls) is persistently elevated.
- Hypertension may be defined by systolic blood pressure, diastolic blood pressure, and/or mean arterial blood pressure.
- Felines may be considered to be hypertensive when they present with a systolic blood pressure of greater than about 150 mm Hg, for example.
- Canines may be considered to be hypertensive when they present with a systolic blood pressure of greater than about 160 mm Hg, for example.
- Equines may be considered to be hypertensive when they present with a systolic blood pressure of greater than about 115 mm Hg, for example.
- Hypertension can increase the risk of many serious medical conditions, such as heart attack, stroke, and kidney disease, and organ damage, among others.
- Guanylate cyclase (GC) stimulators is a group of compounds that can mitigate hypertension. GC stimulators can enhance the activity of guanylate cyclase (GC), an enzyme that relaxes vascular smooth muscles, thereby increasing the diameter of blood vessels and decreasing blood pressure.
- GC guanylate cyclase
- GC stimulators may be very sensitive to UV and/or visible (VIS) radiation or susceptible to hydrolysis.
- VIS visible
- the subject being treated may be unwilling to take the medicine voluntarily due to an unpleasant taste.
- a pharmaceutical formulation for treating hypertension and/or associated diseases comprising: a therapeutically effective amount of a guanylate cyclase (GC) stimulator, wherein the GC stimulator is a compound of Formula (I): or a pharmaceutically acceptable salt thereof.
- GC guanylate cyclase
- the pharmaceutical formulation may be an oral suspension, an oral solution, a solution suitable for intravenous and/or parenteral administration, or a topical medication.
- the pharmaceutical formulation may be an oral suspension.
- the pharmaceutical formulation is an oral suspension that is water-based or oil-based.
- the oral suspension may have a pH value of between about 4.6 and about 9.4, between about 4.7 to 9.3, between about 4.8 and about 9.2, between about 4.9 and about 9.1 , between about 5.0 and about 9.0, between about 5.1 and about 8.9, between about 5.3 and about 8.8, between about 5.4 and about 8.7, between about 5.5 and about 8.6, between about 5.6 and about 8.5, between about 5.7 and about 8.4, between about 5.8 and about 8.3, between about 5.9 and about 8.2, between about 6.0 and about 8.1 , between about 6.1 and about 8.0, between about 6.0 and about 7.9, between about 6.1 and about 7.8, between about 6.2 and about 7.7, between about 6.3 and about 7.7, between about 6.4 and about 7.6, between 6.5 and
- SUBSTITUTE SHEET (RULE 26) about 7.5, between about 6.6 and about 7.4, between about 6.7 and about 7.3, between about 6.8 and about 7.2, between about 6.9 and about 7.1 , between about 4.6 and about 8.3, between about 4.7 and about 8. 3, between about 4.8 and about 8.0, between about 4.9 and about 8.0, between about 5.0 and about 8.0, between about 5.1 and about 8.0, between about 5.2 and about 8.0, between about 5.3 and about 8.0, between about 5.4 and about 8.0, between about 5.5 to 8.0, between about 5.6 and about 8.0, between about
- the pharmaceutical formulation may comprise between about 0.1 and about 2 w/v%, between about 0.25 and about 1 .75 w/v%, between about 0.5 and about 1 .5 w/v%, between about 1 and about 1 .25 w/v%, about 0.1 w/v%, about 0.25 w/v%, about 0.5 w/v%, about 0.75 w/v%, about 1 w/v%, about 1 .5 w/v%, about 1 .75 w/v%, or about 2 w/v% of the GC stimulator.
- the pharmaceutical formulation may further comprise: (i) a total of between about 0.01 and about 10 w/v%, between about 0.1 and about 9 w/v%, between about 0.25 and about 8 w/v%, between about 0.5 and about 7 w/v%, between about 0.75 and about 6 w/v%, between about 1 .0 and about 5 w/v%, between about 1 .25 and about 4 w/v%, between about 1 .5 and about 3 w/v%, or between about 0.1 and about 2 w/v% of one or more buffer; (ii) a total of between about 0.01 and about 5 w/v%,
- SUBSTITUTE SHEET (RULE 26) between about 0.05 and about 4 w/v%, between about 0.075 and about 3 w/v%, between about 0.1 and about 2 w/v%, between about 0.125 and about 1 w/v%, between about 0.15 and about 0.75 w/v%, or between about 0.2 and about 0.5 w/v% of one or more acid; (iii) a total of between about 0.01 and about 5 w/v%, between about 0.25 and about 4 w/v%, between about 0.5 and about 3 w/v%, between about 0.75 and about 2 w/v%, between about 1 and about 1 .75 w/v%, between about 0.15 and about 1 .5 w/v%, between about 0.2 and about 2.0 w/v%, between about 0.3 and about 1.9 w/v%, between about 0.4 and about 1 .8 w/v%, between about 0.5 and about 1 .7 w/v%, between about 0.6
- w/v% between about 0.8 and about 2.3 w/v%, between about 0.9 and about 2.2 w/v%, between about 1.0 and about 2.1 w/v%, between about 1.1 and about 2.0 w/v%, between about 1.2 and about 1 .9 w/v%, between about 1 .3 and about 1.8 w/v%, between about 1 .4 and about 1 .7 w/v%, or between about 1 .5 and about 1 .6 w/v% of one or more preservative; (vi) a total of between about 0.01 and about 5 w/v%, between about 0.01 and about 4 w/v%, between about 0.05 and about 3 w/v%, between about 0.075 and about 2 w/v%, between about 0.1 and about 1 w/v%, between about 0.01 and about 0.2 w/v%, between about 0.05 and about 0.1 w/v%, between about 0.1 and about 0.125 w/v%, between
- SUBSTITUTE SHEET (RULE 26) or between about 0.9 and about 1.1 w/v% of one or more thickener; (viii) a total of between about 0.05 and about 10 w/v%, between about 0.1 and about 9 w/v%, between about 0.25 and about 8 w/v%, between about 0.5 and about 7 w/v%, between about 0.75 and about 6 w/v%, between about 1 .0 and about 5 w/v%, between about 1 .25 and about 4 w/v%, between about 1.5 and about 3 w/v%, or between about 0.1 and about 2 w/v% of one or more additive for pH adjustment; and/or (ix) a total of between about 0.01 and about 5 w/v%, between about 0.01 and about 4 w/v%, between about 0.05 and about 3 w/v%, between about 0.075 and about 2 w/v%, between about 0.1 and about 1 w/v%, between about 0.01 and about
- the pharmaceutical formulation may further comprise (i) a total of 0.1-2 w/v% of one or more buffer; (ii) a total of 0.2-1 w/v% of one or more acid; (iii) a total of 0.2-2.0 w/v% of one or more resuspension aid; (iv) a total of 0.2 w/v% of one or more surfactant for wetting; (v) a total of 0.1 -3 w/v% of one or more preservative; (vi) a total of 1 w/w% of one or more surfactant; (vii) a total of 0.2-2.0 w/v% of one or more thickener; (viii) one or more additive for pH adjustment; and/or (ix) one or more palatant and/or flavoring agent.
- the one or more buffer may comprise a phosphate buffer and/or a tris(hydroxymethyl)aminomethane (Tris) buffer
- the one or more acid may comprise citric acid, citric acid monohydrate, or sorbic acid
- the one or more resuspension aid may comprise microcrystalline cellulose and/or carboxymethylcellulose sodium
- the one or more surfactant for wetting may comprise ethylene oxide/propylene oxide copolymer
- the one or more preservative may comprise methylparaben, propylparaben, n-butyl alcohol, butylated hydroxytoluene (BHT), or a mixture thereof
- the one or more surfactant may comprise glyceryl dibehenate
- the one or more thickener may comprise microcrystalline cellulose and/or carboxymethylcellulose sodium
- the one or more additive may comprise sodium hydroxide
- the GC stimulator may have an enantiomeric purity of at least about 90%, at least about 93%, at least about 95%, at least about 98%, at least
- SUBSTITUTE SHEET (RULE 26) about 99%, at least about 99.1 %, at least about 99.2%, at least about 99.3%, at least about 99.4%, at least about 99.5%, at least about 99.6%, at least about 99.7, at least about 99.77%, at least about 99.8%, at least about 99.9%, or about 100%.
- the enantiomeric purity is measured by High-Performance Liquid Chromatography (HPLC) and/or Ultra-High-Performance Liquid Chromatography (UHPLC).
- the GC stimulator may comprise at least about 90%, at least about 93%, at least about 95%, at least about 98%, at least about 99%, at least about 99.1 %, at least about 99.2%, at least about 99.3%, at least about 99.4%, at least about 99.5%, at least about 99.6%, at least about 99.7, at least about 99.77%, at least about 99.8%, at least about 99.9%, or about 100% of the S enantiomer.
- the GC stimulator may comprise at least about 90%, at least about 93%, at least about 95%, at least about 98%, at least about 99%, at least about 99.1 %, at least about 99.2%, at least about 99.3%, at least about 99.4%, at least about 99.5%, at least about 99.6%, at least about 99.7, at least about 99.77%, at least about 99.8%, at least about 99.9%, or about 100% of the R enantiomer.
- At least about 80%, at least about 85%, at least about 90%, at least about 91 %, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% of the GC stimulator may be maintained in a solid state in the oral suspension.
- the solid state GC stimulator may remain stable in oral suspension at about 25°C, about 30°C, about 35°C, about 40°C, or about 45°C for at least about one week, at least about one month, at least about two months, at least about three months, at least about four months, at least about five months, at least about six months, at least about nine months, at least about one year, or at least about two years with non-significant degradation observed.
- At least about 80%, at least about 85%, at least about 90%, at least about 91 %, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% of the solid state GC stimulator may remain stable.
- stability may be measured via % or area %.
- the solid state GC stimulator may have a half life in oral suspension at about 25°C, about 30°C, about 35°C, about 40°C, or about 45°C of at least about one week, at least about one month, at least about two months, at least about three months, at least about four months, at least about five months, at least about six months, at least about nine months, at least about one year, or at least about two years.
- the solid state GC stimulator may have a half life in oral suspension after
- SUBSTITUTE SHEET (RULE 26) and/or while under exposure to UV/VIS radiation of at least about one week, at least about one month, at least about two months, at least about three months, at least about four months, at least about five months, at least about six months, at least about nine months, at least about one year, or at least about two years.
- the solid state GC stimulator may remain stable in the oral suspension after exposure to UV and/or VIS radiation with a light intensity of about 200 Wh/m2 for about 24 hours with non-significant degradation observed.
- at least about 80%, at least about 85%, at least about 90%, at least about 91 %, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% of the solid state GC stimulator may remain non-degraded.
- degradation may be measured via % or area %.
- the GC stimulator may be capable of remaining stable after dissolving in an aqueous solvent for at least about 1 week under room temperature, or dissolving in an HCI solution of about 0.1 M for at least about 1 week under room temperature, or dissolving in a buffer with a pH value of about 10 for at least about 1 week under room temperature, or dissolving in a phosphate buffer with a pH value of about 7 for at least about 1 week under room temperature, with non-significant hydrolysis observed.
- a method of treating hypertension and/or associated diseases comprising: administering to a subject in need thereof a pharmaceutical formulation comprising a therapeutically effective amount of one or more guanylate cyclase (GC) stimulator described herein.
- GC guanylate cyclase
- the pharmaceutical formulation comprising the therapeutically effective amount of the GC stimulator may be administered by oral route, an intravenous route, a parenteral route, and/or a topical route.
- a method of treating and/or preventing hypertension and/or associated diseases comprising: administering to a subject in need thereof the pharmaceutical formulation comprising a therapeutically effective amount of one or more guanylate cyclase (GC) stimulator in oral suspension described herein.
- GC guanylate cyclase
- a method of treating and/or preventing hypertension and/or associated diseases comprising: orally administering to a subject a pharmaceutically acceptable oral suspension, wherein the oral suspension comprises: a guanylate cyclase (GC) stimulator, wherein the guanylate cyclase (GC) stimulator is a compound of Formula (I) or pharmaceutically acceptable salt thereof; and may optionally comprise: (i) a total of between about 0.01 and about 10 w/v%, between about 0.1 and about 9 w/v%, between about 0.25 and about 8 w/v%, between about 0.5 and about 7 w/v%, between about 0.75 and about 6 w/v%, between about 1 .0 and about 5 w/v%, between about 1 .25 and about 4 w/v%, between about 1 .5 and about 3 w/v%, or between about 0.1 and about 2 w/v
- SUBSTITUTE SHEET (RULE 26) and about 5 w/v%, between about 0.2 and about 4 w/v%, between about 0.3 and about 3 w/v%, between about 0.4 and about 2.7 w/v%, between about 0.5 and about 2.6 w/v%, between about 0.6 and about 2.5 w/v%, between about 0.7 and about 2.4 w/v%, between about 0.8 and about 2.3 w/v%, between about 0.9 and about 2.2 w/v%, between about 1 .0 and about 2.1 w/v%, between about 1.1 and about 2.0 w/v%, between about 1 .2 and about 1 .9 w/v%, between about 1 .3 and about 1 .8 w/v%, between about 1 .4 and about 1 .7 w/v%, or between about 1 .5 and about 1.6 w/v% of one or more preservative; (vi) a total of between about 0.01 and about 5 w/
- the oral suspension may comprise: (i) a total of 0.1-2 w/v% of one or more buffer; (ii) a total of 0.2-1 w/v% of one or more acid; (iii) a total of 0.2- 2.0 w/v% of one or more resuspension aid; (iv) a total of 0.2 w/v% of one or more surfactant for wetting; (v) a total of 0.1 -3 w/v% of one or more preservative; (vi) a total of 1 w/w% of one or more surfactant; (vii) a total of 0.2-2.0 w/v% of one or more thickener; (viii) - 9 -
- SUBSTITUTE SHEET (RULE 26) one or more additive for pH adjustment; and/or (ix) one or more palatant and/or flavoring agent.
- the one or more buffer may comprise a phosphate buffer and/or a tris(hydroxymethyl)aminomethane (Tris) buffer
- the one or more acid may comprise citric acid, citric acid monohydrate, or sorbic acid
- the one or more resuspension aid may comprise microcrystalline cellulose and/or carboxymethylcellulose sodium
- the one or more surfactant for wetting may comprise ethylene oxide/propylene oxide copolymer
- the one or more preservative may comprise methylparaben, propylparaben, n-butyl alcohol, butylated hydroxytoluene (BHT), or a mixture thereof
- the one or more surfactant may comprise glyceryl dibehenate
- the one or more thickener may comprise microcrystalline cellulose and/or carboxymethylcellulose sodium
- the one or more additive may comprise sodium hydroxide
- the oral suspension may have a pH value of between about 4.6 and about 9.4, between about 4.7 to 9.3, between about 4.8 and about 9.2, between about 4.9 and about 9.1 , between about 5.0 and about 9.0, between about 5.1 and about 8.9, between about 5.3 and about 8.8, between about 5.4 and about 8.7, between about 5.5 and about 8.6, between about 5.6 and about 8.5, between about 5.7 and about 8.4, between about 5.8 and about 8.3, between about 5.9 and about 8.2, between about 6.0 and about 8.1 , between about 6.1 and about 8.0, between about 6.0 and about 7.9, between about 6.1 and about 7.8, between about 6.2 and about 7.7, between about 6.3 and about 7.7, between about 6.4 and about 7.6, between 6.5 and about 7.5, between about 6.6 and about 7.4, between about 6.7 and about 7.3, between about 6.8 and about 7.2, between about 6.9 and about 7.1 , between about 4.6 and about 8.3, between about 4.7 and about 8.
- SUBSTITUTE SHEET (RULE 26) Q.7 and about 7.8, between about 6.8 and about 7.7, between about 6.8 and about 7.6, between about 6.8 and about 7.5, between about 6.8 and about 7.4, between about 6.8 and about 7.3, between about 6.9 and about 7.2, between about 6.9 to 7.1 , greater than about 4.5 but less than about 8.1 , greater than about 5.0 but less than about 8.1 , greater than about 5.5 but less than about 8.1 , greater than about 6.0 but less than about 8.1 , greater than about 6.1 but less than about 8.1 , greater than about 6.2 but less than about 8.1 , greater than about 6.3 but less than about 8.1 , greater than about 6.4 but less than about 8.1 , greater than about 6.5 but less than about 8.1 , greater than about 6.6 but less than about 8.1 , greater than about 6.7 but less than about 8.1 , greater than about 6.8 but less than about 8.1 , greater than about 6.9 but less than about 8.1 , greater than about 7.0
- the oral suspension may comprise between about 0.1 and about 2 w/v%, between about 0.25 and about 1 .75 w/v%, between about 0.5 and about 1.5 w/v%, between about 1 and about 1 .25 w/v%, about 0.1 w/v%, about 0.25 w/v%, about 0.5 w/v%, about 0.75 w/v%, about 1 w/v%, about 1 .5 w/v%, about 1 .75 w/v%, or about 2 w/v% of the GC stimulator.
- At least about 80%, at least about 85%, at least about 90%, at least about 91 %, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% of the GC stimulator may be maintained in a solid state in the oral suspension.
- the subject in need thereof may be a vertebrate.
- the subject may be feline, canine, or equine.
- the hypertension and/or associated diseases may be one or more selected from hypertension, resistant hypertension, acute and chronic heart failure, coronary heart disease, stable and unstable angina pectoris, peripheral and cardiac vascular diseases, arrhythmias, disturbances of atrial and ventricular rhythm and conduction disturbances, for example atrioventricular blocks of degree l-lll (AVB l-lll), supraventricular tachyarrhythmia, atrial fibrillation, atrial flutter, ventricular fibrillation, ventricular flutter, ventricular tachyarrhythmia, torsade-de-pointes tachycardia, atrial and ventricular extrasystoles, AV junction extrasystoles, sick-sinus syndrome, syncopes, AV-
- treating the hypertension and/or associated diseases may comprise decreasing or substantially decreasing a mean arterial blood pressure, a systolic blood pressure, and/or a diastolic blood pressure.
- treating the hypertension and/or associated diseases may comprise decreasing a mean arterial blood pressure, a systolic blood pressure, and/or a diastolic blood pressure to about, to within about 1 %, to within about 2%, to within about 3%, to within about 4%, to within about 5%, to within about 10%, to within about 15%, or to within about 20% the blood pressure considered normal for the species treated.
- the plasma concentration of the GC stimulator in the subject may be higher than about 5 pg/L, about 6 pg/L, about 7 pg/L, about 8 pg/L, about 9 pg/L, about 10 pg/L, about 11 pg/L, about 12 pg/L, about 13 pg/L, about 14 pg/L, about 15 pg/L, about 16 pg/L, about 17 pg/L, about 18 pg/L, about 19 pg/L, or about 20 pg/L about 24 hours after administration of the oral suspension.
- the plasma concentration of the GC stimulator in the subject may be higher than about 5 pg/L, about 6 pg/L, about 7 pg/L, about 8 pg/L, about 9 pg/L, about 10 pg/L, about 11 pg/L, about 12 pg/L, about 13 pg/L, about 14 pg/L, about 15 pg/L, about 16 pg/L, about 17 pg/L, about 18 pg/L, about 19 pg/L, or about 20 pg/L about 48 hours after administration of the oral suspension.
- the plasma concentration of the GC stimulator in the subject may be higher than about 5 pg/L, about 6 pg/L, about 7 pg/L, about 8 pg/L, about 9 pg/L, about 10 pg/L, about 11 pg/L, about 12 pg/L, about 13 pg/L, about 14 pg/L, about 15 pg/L, about 16 pg/L, about 17 pg/L, about 18 pg/L, about 19 pg/L, or about 20 pg/L about 60 hours after administration of the oral suspension.
- a dose of the GC stimulator administered to the subject may be about 0.25 mg/kg, about 0.5 mg/kg, about 0.75 mg/kg about 1 mg/kg, about 1 .25 mg/kg, about 1.5 mg/kg, about 1.75 mg/kg, or about 2 mg/kg.
- a dose of the GC stimulator may be administered to the subject four times per day, three times per day, twice per day, once per day, once per two days, once per week, once per month, once per two months, or once per three months.
- the pharmaceutical formulation or oral suspension may be voluntarily consumed by the subject.
- the GC stimulator may be administered to the subject in combination with one or more of a second GC stimulator and/or an additional therapeutic agent.
- the additional therapeutic agent may be selected from (i) one or more organic nitrate and/or NO donor, optionally selected from sodium nitroprusside, nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, molsidomine or SIN-1 , or inhalational NO; (ii) one or more compound that inhibits the degradation of cyclic guanosine monophosphate (cGMP), optionally selected from inhibitors of phosphodiesterases (PDE) 1 , 2 and/or 5, optionally PDE-5 inhibitors, optionally sildenafil, vardenafil, or tadalafil; (iii) one or more antithrombotic agent, optionally selected from platelet aggregation inhibitors, optionally aspir
- cGMP cyclic guanosine monophosphate
- PDE phospho
- a method of forming a pharmaceutically acceptable oral suspension comprising a guanylate cyclase (GC) stimulator, wherein the a guanylate cyclase (GC) stimulator is a compound of Formula (I)
- a pharmaceutically acceptable salt thereof may be provided, the method comprising: mixing the GC of Formula (I) or pharmaceutically acceptable salt thereof with an aqueous or oily solution; and adjusting the pH value to between about 5 and about 14 to form the oral suspension with the GC stimulator dispersed in the solution as insoluble solid particles.
- the pH may be adjusted such that at least about 80%, at least about 85%, at least about 90%, at least about 91 %, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% of the GC stimulator is maintained in a solid state in the oral suspension.
- the pH may be adjusted to between about 4.6 and about 9.4, between about 4.7 to 9.3, between about 4.8 and about 9.2, between about 4.9 and about 9.1 , between about 5.0 and about 9.0, between about 5.1 and about 8.9, between about 5.3 and about 8.8, between about 5.4 and about 8.7, between about 5.5 and about 8.6, between about 5.6 and about 8.5, between about 5.7 and about 8.4, between about 5.8 and about 8.3, between about 5.9 and about 8.2, between about 6.0 and about 8.1 , between about 6.1 and about 8.0, between about 6.0 and about 7.9, between about 6.1 and about 7.8, between about 6.2 and about 7.7, between about 6.3 and about 7.7, between about 6.4 and about 7.6, between 6.5 and about 7.5, between about 6.6 and about 7.4, between about 6.7 and about 7.3, between about 6.8 and about 7.2, between about 6.9 and about 7.1 , between about 4.6 and about 8.3, between about 4.7 and about 8.
- SUBSTITUTE SHEET (RULE 26) about 6.1 and about 8.0, between about 6.4 and about 8.0, between about 6.5 and about 8.0, between about 6.6 and about 7.9, between about 6.7 and about 7.8, between about
- the method may further comprise adding (i) a total of between about 0.01 and about 10 w/v%, between about 0.1 and about 9 w/v%, between about 0.25 and about 8 w/v%, between about 0.5 and about 7 w/v%, between about 0.75 and about 6 w/v%, between about 1 .0 and about 5 w/v%, between about 1 .25 and about 4 w/v%, between about 1 .5 and about 3 w/v%, or between about 0.1 and about 2 w/v% of one or more buffer; (ii) a total of between about 0.01 and about 5 w/v%, between about 0.05 and about 4 w/v%, between about 0.075 and about 3 w/v%, between about 0.1 and about 2 w/v%, between about 0.125 and about 1 w/v%, between about 0.15 and about 0.75 w/v%, or between about 0.2 and about 0.5 w/v% of one or more buffer; (ii)
- SUBSTITUTE SHEET (RULE 26) w/v%, between about 0.075 and about 2 w/v%, between 0.1 and about 1 w/v%, between about 0.005 and about 0.2 w/v%, between about 0.05 and about 0.1 w/v%, between about 0.1 and about 0.125 w/v%, between about 0.1 and about 0.15, or between about 0.1 and about 0.175 w/v% of one or more surfactant for wetting; (v) a total of between about 0.1 and about 5 w/v%, between about 0.2 and about 4 w/v%, between about 0.3 and about 3 w/v%, between about 0.4 and about 2.7 w/v%, between about 0.5 and about 2.6 w/v%, between about 0.6 and about 2.5 w/v%, between about 0.7 and about 2.4 w/v%, between about 0.8 and about 2.3 w/v%, between about 0.9 and about 2.2 w/v%, between about 1
- the method may further comprise adding: (i) a total of 0.1-2 w/v% of one or more buffer; (ii) a total of 0.2-1 w/v% of one or more acid; (iii) a total of 0.2-2.0 w/v% of one or more resuspension aid; (iv) a total of 0.2 w/v% of one or more surfactant for wetting; (v) a total of 0.1 -3 w/v% of one or more preservative; (vi) a total of 1 w/w% of one or more surfactant; (vii) a total of 0.2-2.0 w/v% of one or more thickener; (viii) one or more additive for pH adjustment; and/or (ix) one or more palatant and/or flavoring agent.
- the one or more buffer may comprise a phosphate buffer and/or a tris(hydroxymethyl)aminomethane (Tris) buffer
- the one or more acid may comprise citric acid, citric acid monohydrate, or sorbic acid
- the one or more resuspension aid may comprise microcrystalline cellulose and/or carboxymethylcellulose sodium
- the one or more surfactant for wetting may comprise ethylene oxide/propylene oxide copolymer
- the one or more preservative may comprise methylparaben, propylparaben, n-butyl alcohol, butylated hydroxytoluene (BHT), or a mixture thereof
- the one or more surfactant may comprise glyceryl dibehenate
- the one or more thickener may comprise microcrystalline cellulose and/or carboxymethylcellulose sodium
- the one or more additive may comprise sodium hydroxide
- the oral suspension may comprise between about 0.1 and about 2 w/v%, between about 0.25 and about 1 .75 w/v%, between about 0.5 and about 1.5 w/v%, between about 1 and about 1 .25 w/v%, about 0.1 w/v%, about 0.25 w/v%, about 0.5 w/v%, about 0.75 w/v%, about 1 w/v%, about 1 .5 w/v%, about 1 .75 w/v%, or about 2 w/v% of the GC stimulator.
- the GC stimulator may have an enantiomeric purity of at least about 90%, at least about 93%, at least about 95%, at least about 98%, at least about 99%, at least about 99.1 %, at least about 99.2%, at least about 99.3%, at least about 99.4%, at least about 99.5%, at least about 99.6%, at least about 99.7, at least about 99.77%, at least about 99.8%, at least about 99.9%, or about 100%.
- the enantiomeric purity may be measured by High-Performance Liquid Chromatography (HPLC) and/or Ultra-High-Performance Liquid Chromatography (UHPLC).
- the GC stimulator may comprise at least about 90%, at least about 93%, at least about 95%, at least about 98%, at least about 99%, at least about 99.1 %, at least about 99.2%, at least about 99.3%, at least about 99.4%, at least about 99.5%, at least about 99.6%, at least about 99.7, at least about 99.77%, at least about 99.8%, at least about 99.9%, or about 100% of the S enantiomer.
- the GC stimulator may comprise at least about 90%, at least about 93%, at least about 95%, at least about 98%, at least about 99%, at least about 99.1 %, at least about 99.2%, at least about 99.3%, at least about 99.4%, at least about 99.5%, at least about 99.6%, at least about 99.7, at least about 99.77%, at least about 99.8%, at least about 99.9%, or about 100% of the R enantiomer.
- the solid state GC stimulator may remain stable in oral suspension at about 25°C, about 30°C, about 35°C, about 40°C, or about 45°C for at least about one week, at least about one month, at least about two months, at least about three months, at least about four months, at least about five months, at least about six months, at least about nine months, or at least about one year with non-significant degradation observed.
- At least about 80%, at least about 85%, at least about 90%, at least about 91 %, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% of the solid state GC stimulator may remain stable.
- stability may be measured via % or area %.
- the solid state GC stimulator may have a half life in oral suspension at about 25°C, about 30°C, about 35°C, about 40°C, or about 45°C of at least about one week, at least about one month, at least about two months, at least about three months, at least about four months, at least about five months, at least about six months, at least about nine months, at least about one year, or at least about two years.
- the solid state GC stimulator may have a half life in oral suspension after and/or while under exposure to UV/VIS radiation of at least about one week, at least about one month, at least about two months, at least about three months, at least about four months, at least about five months, at least about six months, at least about nine months, at least about one year, or at least about two years.
- the solid state GC stimulator may remain stable in the oral suspension after exposure to UV and/or VIS radiation with a light intensity of about 200 Wh/m2 for about 24 hours with non-significant degradation observed. In some embodiments, at least about 80%, at least about 85%, at least about 90%, at least about 91 %, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at
- SUBSTITUTE SHEET (RULE 26) least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% of the solid state GC stimulator may remain non-degraded. In some embodiments, degradation may be measured via % or area %.
- the GC stimulator may be capable of remaining stable after dissolving in an aqueous solvent for at least about 1 week under room temperature, or dissolving in an HCI solution of about 0.1 M for at least about 1 week under room temperature, or dissolving in a buffer with a pH value of about 10 for at least about 1 week under room temperature, or dissolving in a phosphate buffer with a pH value of about 7 for at least about 1 week under room temperature, with non-significant hydrolysis observed.
- At least about 80%, at least about 85%, at least about 90%, at least about 91 %, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% of the solid state GC stimulator may remain stable.
- a therapeutically effective amount of pharmaceutical formulation comprising a guanylate cyclase (GC) stimulator, wherein the guanylate cyclase (GC) stimulator is a compound of Formula (I) or a pharmaceutically acceptable salt thereof; for use to treat and/or prevent hypertension and/or associated diseases in a subject in need thereof may be provided.
- a guanylate cyclase (GC) stimulator is a compound of Formula (I) or a pharmaceutically acceptable salt thereof
- the guanylate cyclase (GC) stimulator may be formulated as an oral suspension, an oral solution, a solution suitable for intravenous and/or parenteral administration, or a topical medication.
- the pharmaceutical formulation may be an oral suspension.
- the pharmaceutical formulation may be an oral suspension that is water-based or oil-based.
- the oral suspension may have a pH value of between about 4.6 and about 9.4, between about 4.7 to 9.3, between about 4.8 and about 9.2, between about 4.9 and about 9.1 , between about 5.0 and about 9.0, between about 5.1 and about 8.9, between about 5.3 and about 8.8, between about 5.4 and about 8.7, between about 5.5 and about 8.6, between about 5.6 and about 8.5, between about 5.7 and about 8.4, between about 5.8 and about 8.3, between about 5.9 and about 8.2, between about 6.0 and about 8.1 , between about 6.1 and about 8.0, between about 6.0 and about 7.9, between about 6.1 and about 7.8, between about 6.2 and about 7.7, between about 6.3 and about 7.7, between about 6.4 and about 7.6, between 6.5 and about 7.5, between about 6.6 and about 7.4, between about 6.7 and about 7.3, between about 6.8 and about 7.2, between about 6.9 and about 7.1 , between about 4.6 and about 8.3, between
- the pharmaceutical formulation may comprise between about 0.1 and about 2 w/v%, between about 0.25 and about 1 .75 w/v%, between about 0.5
- SUBSTITUTE SHEET (RULE 26) and about 1 .5 w/v%, between about 1 and about 1 .25 w/v%, about 0.1 w/v%, about 0.25 w/v%, about 0.5 w/v%, about 0.75 w/v%, about 1 w/v%, about 1 .5 w/v%, about 1 .75 w/v%, or about 2 w/v% of the GC stimulator.
- the pharmaceutical formulation may further comprise: (i) a total of between about 0.01 and about 10 w/v%, between about 0.1 and about 9 w/v%, between about 0.25 and about 8 w/v%, between about 0.5 and about 7 w/v%, between about 0.75 and about 6 w/v%, between about 1 .0 and about 5 w/v%, between about 1 .25 and about 4 w/v%, between about 1 .5 and about 3 w/v%, or between about 0.1 and about 2 w/v% of one or more buffer; (ii) a total of between about 0.01 and about 5 w/v%, between about 0.05 and about 4 w/v%, between about 0.075 and about 3 w/v%, between about 0.1 and about 2 w/v%, between about 0.125 and about 1 w/v%, between about 0.15 and about 0.75 w/v%, or between about 0.2 and about 0.5 w/v% of
- SUBSTITUTE SHEET (RULE 26) between about 0.05 and about 0.1 w/v%, between about 0.1 and about 0.125 w/v%, between about 0.1 and about 0.15, or between about 0.1 and about 0.175 w/v% of one or more surfactant; (vii) a total of between about 0.01 and about 5 w/v%, between about 0.25 and about 4 w/v%, between about 0.5 and about 3 w/v%, between about 0.75 and about 2 w/v%, between about 1 and about 1.75 w/v%, between about 0.15 and about 1.5 w/v%, between about 0.2 and about 2.0 w/v%, between about 0.3 and about 1 .9 w/v%, between about 0.4 and about 1 .8 w/v%, between about 0.5 and about 1.7 w/v%, between about 0.6 and about 1 .6 w/v%, between about 0.7 and aboutl .5 w/v%, between about 0.8 and about
- the pharmaceutical formulation may comprises: (i) a total of 0.1-2 w/v% of one or more buffer; (ii) a total of 0.2-1 w/v% of one or more acid; (iii) a total of 0.2-2.0 w/v% of one or more resuspension aid; (iv) a total of 0.2 w/v% of one or more surfactant for wetting; (v) a total of 0.1 -3 w/v% of one or more preservative; (vi) a total of 1 w/w% of one or more surfactant; (vii) a total of 0.2-2.0 w/v% of one or more thickener; (viii) one or more additive for pH adjustment; and/or (ix) one or more palatant and/or flavoring agent.
- the one or more buffer may comprise a phosphate buffer and/or a tris(hydroxymethyl)aminomethane (Tris) buffer
- the one or more acid may comprise citric acid, citric acid monohydrate, or sorbic acid
- the one or more resuspension aid may comprise microcrystalline cellulose and/or carboxymethylcellulose sodium
- the one or more surfactant for wetting may comprise ethylene oxide/propylene oxide copolymer
- the one or more preservative may comprise methylparaben, propylparaben, n-butyl alcohol, butylated hydroxytoluene (BHT), or a mixture thereof
- the one or more surfactant may comprise glyceryl dibehenate
- the one or more surfactant may comprise glyceryl dibehenate
- one or more thickener may comprise microcrystalline cellulose and/or carboxymethylcellulose sodium
- the one or more additive may comprise sodium hydroxide, hydrochloric acid, or a mixture thereof
- the one or more palatant and/or flavoring agent may comprise one or more vanilla flavoring, one or more cheese flavoring, one or more fish flavoring, one or more chicken flavoring, one or more pork flavoring, and/or one or more beef flavoring.
- the phosphate buffer may comprise a dibasic sodium phosphate.
- the GC stimulator may have an enantiomeric purity of at least about 90%, at least about 93%, at least about 95%, at least about 98%, at least about 99%, at least about 99.1 %, at least about 99.2%, at least about 99.3%, at least about 99.4%, at least about 99.5%, at least about 99.6%, at least about 99.7, at least about 99.77%, at least about 99.8%, at least about 99.9%, or about 100%.
- the enantiomeric purity may be measured by High-Performance Liquid Chromatography (HPLC) and/or Ultra-High-Performance Liquid Chromatography (UHPLC).
- the GC stimulator may comprise at least about 90%, at least about 93%, at least about 95%, at least about 98%, at least about 99%, at least about 99.1 %, at least about 99.2%, at least about 99.3%, at least about 99.4%, at least about 99.5%, at least about 99.6%, at least about 99.7, at least about 99.77%, at least about 99.8%, at least about 99.9%, or about 100% of the S enantiomer.
- the GC stimulator may comprise at least about 90%, at least about 93%, at least about 95%, at least about 98%, at least about 99%, at least about 99.1 %, at least about 99.2%, at least about 99.3%, at least about 99.4%, at least about 99.5%, at least about 99.6%, at least about 99.7, at least about 99.77%, at least about 99.8%, at least about 99.9%, or about 100% of the R enantiomer.
- At least about 80%, at least about 85%, at least about 90%, at least about 91 %, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% of the GC stimulator may be maintained in a solid state in the oral suspension.
- the solid state GC stimulator may remain stable in oral suspension at about 25°C, about 30°C, about 35°C, about 40°C, or about 45°C for at least about one week, at least about one month, at least about two months, at least about three months, at least about four months, at least about five months, at least about six months, at least about nine months, or at least about one year with non-significant degradation
- SUBSTITUTE SHEET (RULE 26) observed.
- at least about 80%, at least about 85%, at least about 90%, at least about 91 %, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% of the solid state GC stimulator may remain stable.
- stability may be measured via % or area %.
- the solid state GC stimulator may have a half life in oral suspension at about 25°C, about 30°C, about 35°C, about 40°C, or about 45°C of at least about one week, at least about one month, at least about two months, at least about three months, at least about four months, at least about five months, at least about six months, at least about nine months, at least about one year, or at least about two years.
- the solid state GC stimulator may have a half life in oral suspension after and/or while under exposure to UV and/or VIS radiation of at least about one week, at least about one month, at least about two months, at least about three months, at least about four months, at least about five months, at least about six months, at least about nine months, at least about one year, or at least about two years.
- the solid state GC stimulator may remain stable in the oral suspension after exposure to UV and/or VIS radiation with a light intensity of about 200 Wh/m2 for about 24 hours with non-significant degradation observed.
- at least about 80%, at least about 85%, at least about 90%, at least about 91 %, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% of the solid state GC stimulator may remain non-degraded.
- degradation may be measured via % or area %.
- the GC stimulator may be capable of remaining stable after dissolving in an aqueous solvent for at least about 1 week under room temperature, or dissolving in an HCI solution of about 0.1 M for at least about 1 week under room temperature, or dissolving in a buffer with a pH value of about 10 for at least about 1 week under room temperature, or dissolving in a phosphate buffer with a pH value of about 7 for at least about 1 week under room temperature, with non-significant hydrolysis observed.
- At least about 80%, at least about 85%, at least about 90%, at least about 91 %, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% of the solid state GC stimulator may remain stable.
- the therapeutically effective amount of the GC stimulator may be formulated for administration by an oral route, an intravenous route, a parenteral route, and/or a topical route.
- the subject in need thereof may be a vertebrate.
- the subject may be feline, canine, or equine.
- the hypertension and/or associated diseases may be one or more selected from hypertension, resistant hypertension, acute and chronic heart failure, coronary heart disease, stable and unstable angina pectoris, peripheral and cardiac vascular diseases, arrhythmias, disturbances of atrial and ventricular rhythm and conduction disturbances, for example atrioventricular blocks of degree l-lll (AVB l-lll), supraventricular tachyarrhythmia, atrial fibrillation, atrial flutter, ventricular fibrillation, ventricular flutter, ventricular tachyarrhythmia, torsade-de-pointes tachycardia, atrial and ventricular extrasystoles, AV junction extrasystoles, sick-sinus syndrome, syncopes, AV- node reentry tachycardia, Wolff-Parkinson-White syndrome, acute coronary syndrome (ACS), autoimmune heart diseases (pericarditis, endocarditis, valvulitis,
- treating the hypertension and/or associated diseases may comprise decreasing or substantially decreasing a mean arterial blood pressure, a systolic blood pressure, and/or a diastolic blood pressure.
- treating the hypertension and/or associated diseases may comprise decreasing a mean arterial blood pressure, a systolic blood pressure, and/or a diastolic blood pressure to about, to within about 1 %, to within about 2%, to within about 3%, to within about 4%, to within about 5%, to within about 10%, to within about 15%, or to within about 20% the blood pressure considered normal for the species treated.
- the pharmaceutical formulation may be formulated such that the plasma concentration of the GC stimulator in the subject is higher than about 5 pg/L, about 6 pg/L, about 7 pg/L, about 8 pg/L, about 9 pg/L, about 10 pg/L, about 11 pg/L, about 12 pg/L, about 13 pg/L, about 14 pg/L, about 15 pg/L, about 16 pg/L, about 17 pg/L, about 18 pg/L, about 19 pg/L, or about 20 pg/L about 24 hours after administration of the oral suspension.
- the pharmaceutical formulation may formulated such that plasma concentration of the GC stimulator in the subject is higher than about 5 pg/L, about 6 pg/L, about 7 pg/L, about 8 pg/L, about 9 pg/L, about 10 pg/L, about 11 pg/L, about 12 pg/L, about 13 pg/L, about 14 pg/L, about 15 pg/L, about 16 pg/L, about 17 pg/L, about 18
- SUBSTITUTE SHEET (RULE 26) pg/L, about 19 pg/L, or about 20 pg/L about 48 hours after administration of the oral suspension.
- the pharmaceutical formulation may be formulated such that plasma concentration of the GC stimulator in the subject is higher than about 5 pg/L, about 6 pg/L, about 7 pg/L, about 8 pg/L, about 9 pg/L, about 10 pg/L, about 11 pg/L, about 12 pg/L, about 13 pg/L, about 14 pg/L, about 15 pg/L, about 16 pg/L, about 17 pg/L, about 18 pg/L, about 19 pg/L, or about 20 pg/L about 60 hours after administration of the oral suspension.
- a dose of the GC stimulator may be formulated for administration to the subject at a dosage of about 0.25 mg/kg, about 0.5 mg/kg, about 0.75 mg/kg about 1 mg/kg, about 1 .25 mg/kg, about 1 .5 mg/kg, about 1.75 mg/kg, or about 2 mg/kg.
- a dose of the GC stimulator may be formulated for administration to the subject four times per day, three times per day, twice per day, once per day, once per two days, once per week, once per month, once per two months, or once per three months.
- the GC stimulator may be formulated such that it is voluntarily consumed by the subject.
- the GC stimulator may be formulated for administration to the subject in combination with one or more of a second GC stimulator and/or an additional therapeutic agent.
- the additional therapeutic agent may be selected from (i) one or more organic nitrate and/or NO donor, optionally selected from sodium nitroprusside, nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, molsidomine or SIN-1 , or inhalational NO; (ii) one or more compound that inhibits the degradation of cyclic guanosine monophosphate (cGMP), optionally selected from inhibitors of phosphodiesterases (PDE) 1 , 2 and/or 5, optionally PDE-5 inhibitors, optionally sildenafil, vardenafil, or tadalafil; (iii) one or more antithrombotic agent, optionally selected from platelet aggregation inhibitors, optionally aspirin, clopidogrel, ticlopidine or dipyridamole; anticoagulants; thrombin inhibitors, optionally ximelagatran, dabigatran, melagatran
- SUBSTITUTE SHEET (RULE 26) endothelin antagonists; renin inhibitors; alpha-blockers; beta-blockers, optionally propranolol, atenolol, timolol, pindolol, alprenolol, oxprenolol, penbutolol, bupranolol, metipranolol, nadolol, mepindolol, carazolol, sotalol, metoprolol, betaxolol, celiprolol, bisoprolol, carteolol, esmolol, labetalol, carvedilol, adaprolol, landiolol, nebivolol, epanolol or bucindolol; mineralocorticoid receptor antagonists; or diuretics; (v) one or more active substance that alters fat metabolism, optional
- FIG. 1 is an exemplary chart showing the plasma concentration of GC stimulator of Formula (I) after administering formulations comprising GC stimulator of Formula (I) to cats.
- FIG. 2 is an exemplary chart showing the plasma concentration of GC stimulator of Formula (I) after administering formulations comprising GC stimulator of Formula (I) to cats.
- FIG. 3 is an exemplary chart showing the plasma concentration of GC stimulator of Formula (I) after administering formulations comprising GC stimulator of Formula (I) to cats.
- Fig. 4 is a flow chart illustrating the blood pressure measurement plan of Example 8.
- GC stimulators may be very sensitive to UV and/or VIS radiation or susceptible to hydrolysis.
- the subject being treated may be unwilling to take the medicine voluntarily due to an unpleasant taste.
- the compounds of the present invention include Guanylate Cyclase (GC) Stimulators having Formula (I):
- the compounds of the present invention include Guanylate Cyclase (GC) Stimulators having the chemical name N-(2-amino-5,5,5-trifluoro-2-methylpentyl)-8-[(2,6- difluorobenzyl)oxy]-2,6-dimethylimidazo[1 ,2-a]pyridine-3-carboxamide.
- GC Guanylate Cyclase
- the compounds of the present disclosure also include pharmaceutically acceptable salts of the compounds disclosed herein.
- pharmaceutically acceptable salt refers to a salt formed by the addition of a pharmaceutically acceptable acid or base to a compound disclosed herein.
- pharmaceutically acceptable refers to a substance that is acceptable for use in pharmaceutical applications from a toxicological perspective and does not adversely interact with the active ingredient.
- salts include, but are not limited to, those derived from organic and inorganic acids such as, but not limited to, acetic, lactic, citric, cinnamic, tartaric, succinic, fumaric, maleic, malonic, mandelic, malic, oxalic, propionic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, glycolic, pyruvic, methanesulfonic, ethanesulfonic, toluenesulfonic, salicylic, benzoic, and similarly known acceptable acids. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing
- the GC stimulator of the present disclosure has an enantiomeric purity of at least about 90%, at least about 93%, at least about 95%, at least about 98%, at least about 99%, at least about 99.1 %, at least about 99.2%, at least about 99.3%, at least about 99.4%, at least about 99.5%, at least about 99.6%, at least about 99.7, at least about 99.77%, at least about 99.8%, at least about 99.9%, or about 100%.
- the enantiomeric purity is measured by High-Performance Liquid Chromatography (HPLC) and/or Ultra-High-Performance Liquid Chromatography (UHPLC).
- the GC stimulator of the present disclosure comprises at least about 90%, at least about 93%, at least about 95%, at least about 98%, at least about 99%, at least about 99.1 %, at least about 99.2%, at least about 99.3%, at least about 99.4%, at least about 99.5%, at least about 99.6%, at least about 99.7, at least about 99.77%, at least about 99.8%, at least about 99.9%, or about 100% of the S enantiomer.
- the GC stimulator of the present disclosure comprises at least about 90%, at least about 93%, at least about 95%, at least about 98%, at least about 99%, at least about 99.1 %, at least about 99.2%, at least about 99.3%, at least about 99.4%, at least about 99.5%, at least about 99.6%, at least about 99.7, at least about 99.77%, at least about 99.8%, at least about 99.9%, or about 100% of the R enantiomer.
- the GC stimulator remains stable after dissolving in an aqueous solvent for at least about 1 week under room temperature, or dissolving in an HCI solution of about 0.1 M for at least about 1 week under room temperature, or dissolving in a buffer with a pH value of about 10 for at least about 1 week under room temperature, or dissolving in a phosphate buffer with a pH value of about 7 for at least about 1 week under room temperature, with non-significant hydrolysis observed.
- the GC stimulators of the present disclosure may be synthesized by known methods of chemical synthesis. In some embodiments, GC stimulators of the present disclosure are synthesized using methods set forth in US Patent No. 10,052,312, which is incorporated by reference in its entirety. In some embodiments, GC stimulators of the present disclosure are synthesized using methods set forth in US Patent Application Publication No. US 2015/0274719, which is incorporated by reference in its entirety.
- a method of forming a pharmaceutically acceptable oral suspension comprising a guanylate cyclase (GC) stimulator, wherein the a guanylate cyclase (GC) stimulator is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, is provided, the method comprising: (i) mixing the GC of Formula (I) or pharmaceutically acceptable salt thereof with an aqueous or oily solution; and (ii) adjusting the pH value to between about 5 and about 14 to form the oral suspension with the GC stimulator dispersed in the solution as insoluble solid particles.
- a guanylate cyclase (GC) stimulator is a compound of Formula (I) or a pharmaceutically acceptable salt thereof
- the method comprising: (i) mixing the GC of Formula (I) or pharmaceutically acceptable salt thereof with an aqueous or oily solution; and (ii) adjusting the pH value to between about 5 and about 14 to form the oral suspension with the GC stimulator dispersed in the solution as insoluble
- the pH is adjusted such that at least about 80%, at least about 85%, at least about 90%, at least about 91 %, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% of the GC stimulator is maintained in a solid state in the oral suspension.
- the pH is adjusted to between about 4.6 and about 9.4, between about 4.7 to 9.3, between about 4.8 and about 9.2, between about 4.9 and about 9.1 , between about 5.0 and about 9.0, between about 5.1 and about 8.9, between about
- SUBSTITUTE SHEET (RULE 26) 5.3 and about 8.8, between about 5.4 and about 8.7, between about 5.5 and about 8.6, between about 5.6 and about 8.5, between about 5.7 and about 8.4, between about 5.8 and about 8.3, between about 5.9 and about 8.2, between about 6.0 and about 8.1 , between about 6.1 and about 8.0, between about 6.0 and about 7.9, between about 6.1 and about 7.8, between about 6.2 and about 7.7, between about 6.3 and about 7.7, between about 6.4 and about 7.6, between 6.5 and about 7.5, between about 6.6 and about 7.4, between about 6.7 and about 7.3, between about 6.8 and about 7.2, between about 6.9 and about 7.1 , between about 4.6 and about 8.3, between about 4.7 and about 8.
- the method further comprises adding (i) a total of between about 0.01 and about 10 w/v%, between about 0.1 and about 9 w/v%, between about 0.25 and about 8 w/v%, between about 0.5 and about 7 w/v%, between about 0.75 and about 6 w/v%, between about 1 .0 and about 5 w/v%, between about 1 .25 and about 4 w/v%, between about 1 .5 and about 3 w/v%, or between about 0.1 and about 2 w/v% of
- SUBSTITUTE SHEET (RULE 26) one or more buffer; (ii) a total of between about 0.01 and about 5 w/v%, between about 0.05 and about 4 w/v%, between about 0.075 and about 3 w/v%, between about 0.1 and about 2 w/v%, between about 0.125 and about 1 w/v%, between about 0.15 and about 0.75 w/v%, or between about 0.2 and about 0.5 w/v% of one or more acid; (iii) a total of between about 0.01 and about 5 w/v%, between about 0.25 and about 4 w/v%, between about 0.5 and about 3 w/v%, between about 0.75 and about 2 w/v%, between about 1 and about 1 .75 w/v%, between about 0.15 and about 1 .5 w/v%, between about 0.2 and about 2.0 w/v%, between about 0.3 and about 1 .9 w/v%, between about 0.4 and about 1
- SUBSTITUTE SHEET (RULE 26) and about 1 .3 w/v%, between about 0.8 and about 1.2 w/v%, or between about 0.9 and about 1.1 w/v% of one or more thickener; (viii) a total of between about 0.05 and about 10 w/v%, between about 0.1 and about 9 w/v%, between about 0.25 and about 8 w/v%, between about 0.5 and about 7 w/v%, between about 0.75 and about 6 w/v%, between about 1.0 and about 5 w/v%, between about 1 .25 and about 4 w/v%, between about 1 .5 and about 3 w/v%, or between about 0.1 and about 2 w/v% of one or more additive for pH adjustment; and/or (ix) a total of between about 0.01 and about 5 w/v%, between about 0.01 and about 4 w/v%, between about 0.05 and about 3 w/v%, between about 0.075 and about
- the method further comprises adding: (i) a total of 0.1-2 w/v% of one or more buffer; (ii) a total of 0.2-1 w/v% of one or more acid; (iii) a total of 0.2- 2.0 w/v% of one or more resuspension aid; (iv) a total of 0.2 w/v% of one or more surfactant for wetting; (v) a total of 0.1 -3 w/v% of one or more preservative; (vi) a total of 1 w/w% of one or more surfactant; (vii) a total of 0.2-2.0 w/v% of one or more thickener; (viii) one or more additive for pH adjustment; and/or (ix) one or more palatant and/or flavoring agent.
- the one or more buffer comprises a phosphate buffer and/or a tris(hydroxymethyl)aminomethane (Tris) buffer
- the one or more acid comprises citric acid, citric acid monohydrate, or sorbic acid
- the one or more resuspension aid comprises microcrystalline cellulose and/or carboxymethylcellulose sodium
- the one or more surfactant for wetting comprises ethylene oxide/propylene oxide copolymer
- the one or more preservative comprises methylparaben, propylparaben, n-butyl alcohol, butylated hydroxytoluene (BHT), or a mixture thereof
- the one or more surfactant comprises glyceryl dibehenate
- the one or more thickener comprises microcrystalline cellulose and/or carboxymethylcellulose sodium
- the one or more additive comprises sodium hydroxide, hydrochloric acid, or a mixture thereof
- the phosphate buffer if present, comprises a dibasic sodium phosphate.
- the oral suspension comprises between about 0.1 and about 2 w/v%, between about 0.25 and about 1 .75 w/v%, between about 0.5 and about 1 .5
- SUBSTITUTE SHEET (RULE 26) w/v%, between about 1 and about 1 .25 w/v%, about 0.1 w/v%, about 0.25 w/v%, about 0.5 w/v%, about 0.75 w/v%, about 1 w/v%, about 1 .5 w/v%, about 1 .75 w/v%, or about 2 w/v% of the GC stimulator.
- the GC stimulator has an enantiomeric purity of at least about 90%, at least about 93%, at least about 95%, at least about 98%, at least about 99%, at least about 99.1 %, at least about 99.2%, at least about 99.3%, at least about 99.4%, at least about 99.5%, at least about 99.6%, at least about 99.7, at least about 99.77%, at least about 99.8%, at least about 99.9%, or about 100%.
- the enantiomeric purity is measured by High-Performance Liquid Chromatography (HPLC) and/or Ultra-High-Performance Liquid Chromatography (UHPLC).
- the GC stimulator comprises at least about 90%, at least about 93%, at least about 95%, at least about 98%, at least about 99%, at least about 99.1 %, at least about 99.2%, at least about 99.3%, at least about 99.4%, at least about 99.5%, at least about 99.6%, at least about 99.7, at least about 99.77%, at least about 99.8%, at least about 99.9%, or about 100% of the S enantiomer.
- the GC stimulator comprises at least about 90%, at least about 93%, at least about 95%, at least about 98%, at least about 99%, at least about 99.1 %, at least about 99.2%, at least about 99.3%, at least about 99.4%, at least about 99.5%, at least about 99.6%, at least about 99.7, at least about 99.77%, at least about 99.8%, at least about 99.9%, or about 100% of the R enantiomer.
- the solid state GC stimulator remains stable in oral suspension at about 25°C, about 30°C, about 35°C, about 40°C, or about 45°C for at least about one week, at least about one month, at least about two months, at least about three months, at least about four months, at least about five months, at least about six months, at least about nine months, at least about one year, or at least about two years with nonsignificant degradation observed.
- At least about 80%, at least about 85%, at least about 90%, at least about 91 %, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% of the solid state GC stimulator remains stable.
- the stability is measured by any suitable method such as known methods. In some embodiments, stability is measured via % or area %.
- the solid state GC stimulator may have a half life in oral suspension at about 25°C, about 30°C, about 35°C, about 40°C, or about 45°C of at least about one week, at least about one month, at least about two months, at least about three
- SUBSTITUTE SHEET (RULE 26) months at least about four months, at least about five months, at least about six months, at least about nine months, at least about one year, or at least about two years.
- the solid state GC stimulator has a half life in oral suspension after and/or while under exposure to UV/VIS radiation of at least about one week, at least about one month, at least about two months, at least about three months, at least about four months, at least about five months, at least about six months, at least about nine months, at least about one year, or at least about two years.
- the solid state GC stimulator remains stable in the oral suspension after exposure to UV and/or VIS radiation with a light intensity of about 200 Wh/m2 for about 24 hours with non-significant degradation observed.
- the degradation is measured by any suitable method such as known methods.
- degradation is measured via % or area %.
- composition refers to a preparation which is in such form as to permit the biological activity of the active ingredient(s) to be effective, and which contains no additional components that are unacceptably toxic to a subject to which the formulation would be administered.
- “Pharmaceutically acceptable” may refer to a composition, component, or compound that is generally safe, that is non-toxic or has toxicity that is acceptable in consideration of any benefits conferred, and/or that is generally considered acceptable for veterinary and/or human pharmaceutical use. “Pharmaceutically acceptable” may refer to a composition, component, or compound that is approved for veterinary and/or human use by a regulatory agency, such as, but not limited to, the United States Food and Drug Administration, the European Medicines Agency, and/or other similar agency, and/or that is listed in the U.S. Pharmacopeia or other recognized pharmacopeia.
- a regulatory agency such as, but not limited to, the United States Food and Drug Administration, the European Medicines Agency, and/or other similar agency, and/or that is listed in the U.S. Pharmacopeia or other recognized pharmacopeia.
- a “pharmaceutically acceptable carrier” refers to a non-toxic solid, semisolid, or liquid filler, diluent, encapsulating material, formulation auxiliary, or carrier conventional in the art for use with a therapeutic agent that together comprise a “pharmaceutical composition” for administration to a subject.
- a pharmaceutically acceptable carrier is non- toxic to recipients at the dosages and concentrations employed and is compatible with
- SUBSTITUTE SHEET (RULE 26) other ingredients of the formulation.
- the pharmaceutically acceptable carrier is appropriate for the formulation employed.
- pharmaceutically acceptable carriers include alumina; aluminum stearate; lecithin; serum proteins, such as human serum albumin, canine, feline, equine or other animal albumin; buffers such as phosphate, citrate, tromethamine or HEPES buffers; glycine; sorbic acid; potassium sorbate; partial glyceride mixtures of saturated vegetable fatty acids; water; salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, or magnesium trisilicate; polyvinyl pyrrolidone, cellulose-based substances; polyethylene glycol; sucrose; mannitol; or amino acids including, but not limited to, arginine.
- a “therapeutically effective amount” of a substance/molecule, agonist or antagonist may vary according to factors such as the type of disease to be treated, the disease state, the seventy and course of the disease, the type of therapeutic purpose, any previous therapy, the clinical history, the response to prior treatment, the discretion of the attending veterinarian, age, sex, and weight of the animal, and the ability of the substance/molecule, agonist or antagonist to elicit a desired response in the animal.
- a therapeutically effective amount is also one in which any toxic or detrimental effects of the substance/molecule, agonist or antagonist are outweighed by the therapeutically beneficial effects.
- a therapeutically effective amount may be delivered in one or more administrations.
- a therapeutically effective amount refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or prophylactic result.
- ICso means “half maximal inhibitory concentration,” which is the concentration of the test compound that is required to inhibit a biological process or biological component by 50% in vitro.
- ECso means “half maximal effective concentration,” which is the concentration of the test compound that is required to obtain a 50% effect.
- a pharmaceutical formulation for treating hypertension and/or associated diseases comprising: a therapeutically effective amount of a guanylate cyclase (GC) stimulator, wherein the GC stimulator is a compound of Formula (I):
- GC guanylate cyclase
- the pharmaceutical formulation is an oral suspension, an oral solution, a solution suitable for intravenous and/or parenteral administration, or a topical medication.
- the pharmaceutical formulation is an oral suspension.
- the oral suspension is water-based or oil-based.
- the oral suspension has a pH value of between about 4.6 and about 9.4, between about 4.7 to 9.3, between about 4.8 and about 9.2, between about 4.9 and about 9.1 , between about 5.0 and about 9.0, between about 5.1 and about 8.9, between about 5.3 and about 8.8, between about 5.4 and about 8.7, between about 5.5 and about 8.6, between about 5.6 and about 8.5, between about 5.7 and about 8.4, between about 5.8 and about 8.3, between about 5.9 and about 8.2, between about 6.0 and about 8.1 , between about 6.1 and about 8.0, between about 6.0 and about 7.9, between about 6.1 and about 7.8, between about 6.2 and about 7.7, between about 6.3 and about 7.7, between about 6.4 and about 7.6, between 6.5 and about 7.5, between about 6.6 and about 7.4, between about 6.7 and about 7.3, between about 6.8 and about 7.2, between about 6.9 and about 7.1 , between about 4.6 and about 8.3, between about
- SUBSTITUTE SHEET between about 6.9 and about 7.2, between about 6.9 to 7.1 , greater than about 4.5 but less than about 8.1 , greater than about 5.0 but less than about 8.1 , greater than about 5.5 but less than about 8.1 , greater than about 6.0 but less than about 8.1 , greater than about 6.1 but less than about 8.1 , greater than about 6.2 but less than about 8.1 , greater than about 6.3 but less than about 8.1 , greater than about 6.4 but less than about 8.1 , greater than about 6.5 but less than about 8.1 , greater than about 6.6 but less than about 8.1 , greater than about 6.7 but less than about 8.1 , greater than about 6.8 but less than about 8.1 , greater than about 6.9 but less than about 8.1 , greater than about 7.0 but less than about 8.1 , greater than about 7.1 but less than about 8.1 , greater than about 7.2 but less than about 8.1 , greater than about 7.3 but less than about 8.1 , greater than about 7.
- the pharmaceutical formulation comprises between about 0.1 and about 2 w/v%, between about 0.25 and about 1 .75 w/v%, between about 0.5 and about 1 .5 w/v%, between about 1 and about 1 .25 w/v%, about 0.1 w/v%, about 0.25 w/v%, about 0.5 w/v%, about 0.75 w/v%, about 1 w/v%, about 1 .5 w/v%, about 1 .75 w/v%, or about 2 w/v% of the GC stimulator.
- the pharmaceutical formulation further comprises: (i) a total of between about 0.01 and about 10 w/v%, between about 0.1 and about 9 w/v%, between about 0.25 and about 8 w/v%, between about 0.5 and about 7 w/v%, between about 0.75 and about 6 w/v%, between about 1 .0 and about 5 w/v%, between about 1 .25 and about 4 w/v%, between about 1 .5 and about 3 w/v%, or between about 0.1 and about 2 w/v% of one or more buffer; (ii) a total of between about 0.01 and about 5 w/v%, between about 0.05 and about 4 w/v%, between about 0.075 and about 3 w/v%, between about 0.1 and about 2 w/v%, between about 0.125 and about 1 w/v%, between about 0.15 and about 0.75 w/v%, or between about 0.2 and about 0.5 w/v% of one or more buffer; (ii)
- SUBSTITUTE SHEET (RULE 26) 0.01 and about 5 w/v%, between about 0.01 and about 4 w/v%, between about 0.05 and about 3 w/v%, between about 0.075 and about 2 w/v%, between 0.1 and about 1 w/v%, between about 0.005 and about 0.2 w/v%, between about 0.05 and about 0.1 w/v%, between about 0.1 and about 0.125 w/v%, between about 0.1 and about 0.15, or between about 0.1 and about 0.175 w/v% of one or more surfactant for wetting; (v) a total of between about 0.1 and about 5 w/v%, between about 0.2 and about 4 w/v%, between about 0.3 and about 3 w/v%, between about 0.4 and about 2.7 w/v%, between about 0.5 and about 2.6 w/v%, between about 0.6 and about 2.5 w/v%, between about 0.7 and about
- w/v% between about 0.8 and about 2.3 w/v%, between about 0.9 and about 2.2 w/v%, between about 1.0 and about 2.1 w/v%, between about 1.1 and about 2.0 w/v%, between about 1.2 and about 1 .9 w/v%, between about 1 .3 and about 1.8 w/v%, between about 1 .4 and about 1 .7 w/v%, or between about 1 .5 and about 1 .6 w/v% of one or more preservative; (vi) a total of between about 0.01 and about 5 w/v%, between about 0.01 and about 4 w/v%, between about 0.05 and about 3 w/v%, between about 0.075 and about 2 w/v%, between about 0.1 and about 1 w/v%, between about 0.01 and about 0.2 w/v%, between about 0.05 and about 0.1 w/v%, between about 0.1 and about 0.125 w/v%, between
- the pharmaceutical formulation comprises: (i) a total of 0.1-2 w/v% of one or more buffer; (ii) a total of 0.2-1 w/v% of one or more acid; (iii) a total of 0.2-2.0 w/v% of one or more resuspension aid; (iv) a total of 0.2 w/v% of one or more surfactant for wetting; (v) a total of 0.1 -3 w/v% of one or more preservative; (vi) a total of 1 w/w% of one or more surfactant; (vii) a total of 0.2-2.0 w/v% of one or more thickener; (viii) one or more additive for pH adjustment; and/or (ix) one or more palatant and/or flavoring agent.
- the one or more buffer comprises a phosphate buffer and/or a tris(hydroxymethyl)aminomethane (Tris) buffer
- the one or more acid comprises citric acid, citric acid monohydrate, or sorbic acid
- the one or more resuspension aid comprises microcrystalline cellulose and/or carboxymethylcellulose sodium
- the one or more surfactant for wetting comprises ethylene oxide/propylene oxide copolymer
- the one or more preservative comprises methylparaben, propylparaben, n-butyl alcohol, butylated hydroxytoluene (BHT), or a mixture thereof
- the one or more surfactant comprises glyceryl dibehenate
- the one or more thickener comprises microcrystalline cellulose and/or carboxymethylcellulose sodium
- the one or more additive comprises sodium hydroxide, hydrochloric acid, or
- the GC stimulator is maintained in a solid state in the oral suspension. In some embodiments, at least about 80%, at least about 85%, at least about 90%, at least about 91 %, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% of the GC stimulator is maintained in a solid state in the oral suspension.
- the solid state GC stimulator remains stable in oral suspension at about 25°C, about 30°C, about 35°C, about 40°C, or about 45°C for at least about one week, at least about one month, at least about two months, at least about three months, at least about four months, at least about five months, at least about six months, at least about nine months, or at least about one year with non-significant degradation observed.
- SUBSTITUTE SHEET (RULE 26) least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% of the solid state GC stimulator remains stable.
- stability is measured by any suitable method, such as known methods. In some embodiments, stability is measured via % or area %.
- the solid state GC stimulator has a half life in oral suspension at about 25°C, about 30°C, about 35°C, about 40°C, or about 45°C of at least about one week, at least about one month, at least about two months, at least about three months, at least about four months, at least about five months, at least about six months, at least about nine months, at least about one year, or at least about two years.
- the solid state GC stimulator has a half life in oral suspension after and/or while under exposure to UV/VIS radiation of at least about one week, at least about one month, at least about two months, at least about three months, at least about four months, at least about five months, at least about six months, at least about nine months, at least about one year, or at least about two years.
- the solid state GC stimulator remains stable in oral suspension after exposure to UV and/or VIS radiation with a light intensity of about 200 Wh/m2 for about 24 hours with non-significant degradation observed.
- degradation is measured by any suitable method, such as known methods.
- degradation is measured via % or area %.
- a method of treating hypertension and/or associated diseases comprising administering to a subject in need thereof a pharmaceutical formulation comprising a therapeutically effective amount of a guanylate cyclase (GC) described herein is provided.
- a pharmaceutical formulation comprising a therapeutically effective amount of a guanylate cyclase (GC) described herein is provided.
- GC guanylate cyclase
- the pharmaceutical formulation comprising the therapeutically effective amount of the GC stimulator is administered by oral route, an intravenous route, a parenteral route, and/or a topical route.
- a method of treating and/or preventing hypertension and/or associated diseases comprising administering to a subject in need thereof the pharmaceutical formulation comprising a therapeutically effective amount of the guanylate cyclase (GC) stimulator in oral suspension described herein is provided.
- GC guanylate cyclase
- the subject in need thereof is a vertebrate.
- the subject is feline, canine, or equine.
- the plasma concentration of the GC stimulator in the subject is higher than about 5 pg/L, about 6 pg/L, about 7 pg/L, about 8 pg/L, about 9 pg/L, about 10 pg/L, about 11 pg/L, about 12 pg/L, about 13 pg/L, about 14 pg/L, about 15 pg/L, about 16 pg/L, about 17 pg/L, about 18 pg/L, about 19 pg/L, or about 20 pg/L about 24 hours after administration of the oral suspension.
- the plasma concentration of the GC stimulator in the subject is higher than about 5 pg/L, about 6 pg/L, about 7 pg/L, about 8 pg/L, about 9 pg/L, about 10 pg/L, about 11 pg/L, about 12 pg/L, about 13 pg/L, about 14 pg/L, about 15 pg/L, about 16 pg/L, about 17 pg/L, about 18 pg/L, about 19 pg/L, or about 20 pg/L about 48 hours after administration of the oral suspension.
- the plasma concentration of the GC stimulator in the subject is higher than about 5 pg/L, about 6 pg/L, about 7 pg/L, about 8 pg/L, about 9 pg/L, about 10 pg/L, about 11 pg/L, about 12 pg/L, about 13 pg/L, about 14 pg/L, about 15 pg/L, about 16 pg/L, about 17 pg/L, about 18 pg/L, about 19 pg/L, or about 20 pg/L about 60 hours after administration of the oral suspension.
- a dose of the GC stimulator administered to the subject is about 0.25 mg/kg, about 0.5 mg/kg, about 0.75 mg/kg about 1 mg/kg, about 1 .25 mg/kg, about 1.5 mg/kg, about 1 .75 mg/kg, or about 2 mg/kg.
- a dose of the GC stimulator is administered to the subject four times per day, three times per day, twice per day, once per day, once per two days, once per week, once per month, once per two months, or once per three months.
- the pharmaceutical formulation or oral suspension is voluntarily consumed by the subject.
- one or more formulations of a GC stimulator described herein described herein further comprises a second GC stimulator and/or one or more additional therapeutic agent.
- one or more methods of treatment described herein comprises administration of and/or one or more additional therapeutic agent.
- one or more additional therapeutic agent is selected from those set forth in US Patent No. 10,052,312, which is incorporated by reference in its entirety.
- one or more additional therapeutic agent is selected from those set forth in US Patent Application Publication No. US 2015/0274719.
- the additional therapeutic agent is selected from (i) one or more organic nitrate and/or NO donor, optionally selected from sodium nitroprusside, nitroglycerin,
- SUBSTITUTE SHEET (RULE 26) isosorbide mononitrate, isosorbide dinitrate, molsidomine or SIN-1 , or inhalational NO; (ii) one or more compound that inhibits the degradation of cyclic guanosine monophosphate (cGMP), optionally selected from inhibitors of phosphodiesterases (PDE) 1 , 2 and/or 5, optionally PDE-5 inhibitors, optionally sildenafil, vardenafil, or tadalafil; (iii) one or more antithrombotic agent, optionally selected from platelet aggregation inhibitors, optionally aspirin, clopidogrel, ticlopidine or dipyridamole; anticoagulants; thrombin inhibitors, optionally ximelagatran, dabigatran, melagatran, bivalirud in or Clexane; or prof ibrinolytic substances; (iv) one or more active substance for lowering blood pressure, optionally
- Administration of one or more GC stimulators of the present disclosure with or in combination with one or more further therapeutic agents includes simultaneous (concurrent) and consecutive or sequential administration in any order.
- concurrently is used herein to refer to administration of two or more therapeutic agents, where at least part of the administration overlaps in time or where the administration of one therapeutic agent falls within a short period of time relative to administration of the other therapeutic agent.
- the two or more therapeutic agents are administered
- SUBSTITUTE SHEET (RULE 26) with a time separation of no more than about a specified number of minutes.
- subsequentially is used herein to refer to administration of two or more therapeutic agents where the administration of one or more agent(s) continues after discontinuing the administration of one or more other agent(s), or wherein administration of one or more agent(s) begins before the administration of one or more other agent(s).
- administration of the two or more therapeutic agents are administered with a time separation of more than about a specified number of minutes.
- in conjunction with refers to administration of one treatment modality in addition to another treatment modality.
- in conjunction with refers to administration of one treatment modality before, during or after administration of the other treatment modality to the animal.
- one or more of the formulations and/or methods described herein are used to treat and/or prevent diseases and/or conditions set forth in US Patent No. 10,052,312, which is incorporated by reference in its entirety. In some embodiments, one or more of the formulation(s) and/or method(s) described herein are used to treat and/or prevent diseases and/or conditions set forth in US Patent Application Publication No. US 2015/0274719. In some embodiments, one or more of the formulations and/or methods set forth herein is used to treat and/or prevent hypertension and/or one or more associated diseases.
- the hypertension and/or associated diseases is one or more selected from hypertension, resistant hypertension, acute and chronic heart failure, coronary heart disease, stable and unstable angina pectoris, peripheral and cardiac vascular diseases, arrhythmias, disturbances of atrial and ventricular rhythm and conduction disturbances, for example atrioventricular blocks of degree l-lll (AVB l-lll), supraventricular tachyarrhythmia, atrial fibrillation, atrial flutter, ventricular fibrillation, ventricular flutter, ventricular tachyarrhythmia, torsade-de-pointes tachycardia, atrial and ventricular extrasystoles, AV junction extrasystoles, sick-sinus syndrome, syncopes, AV-node reentry tachycardia, Wolff-Parkinson-White syndrome, acute coronary syndrome (ACS), autoimmune heart diseases (pericarditis, endocarditis, valvulitis, aortiti
- treatment is an approach for obtaining beneficial or desired clinical results.
- Treatment covers any administration or application of a
- SUBSTITUTE SHEET (RULE 26) therapeutic for disease in a mammal, including a companion animal.
- beneficial or desired clinical results include, but are not limited to, any one or more of: alleviation of one or more symptoms, diminishment of extent of disease, preventing or delaying spread of disease, preventing or delaying recurrence of disease, delay or slowing of disease progression, amelioration of the disease state, inhibiting the disease or progression of the disease, inhibiting or slowing the disease or its progression, arresting its development, and remission (whether partial or total).
- treatment is a reduction of pathological consequence of a proliferative disease.
- the methods provided herein contemplate any one or more of these aspects of treatment. Inline with the above, the term treatment does not require one-hundred percent removal of all aspects of the disorder.
- prevention or “prophylaxis” is an approach for obtaining beneficial or desired clinical results.
- “Prevention” or “prophylaxis” as used herein covers any administration or application of a therapeutic for disease in a mammal, including a companion animal.
- beneficial or desired clinical results include, but are not limited to, any one or more of: preventing or delaying occurrence of disease, preventing or delaying spread of disease, and/or preventing or delaying recurrence of disease.
- prevention is a reduction, prevention, or delay of pathological consequence of a proliferative disease. The methods provided herein contemplate any one or more of these aspects of prevention. In-line with the above, the term prevention or prophylaxis does not require permanent prevention, but rather contemplates delas of any desirable period of time, such as by days, weeks, months, and/or years.
- To “decrease”, “reduce”, or “inhibit” means to decrease, reduce, lower, or arrest an activity, function, or amount as compared to a reference. In some embodiments, by “decrease”, “reduce”, or “inhibit” is meant the ability to cause an overall decrease of 20% or greater. In some embodiments, by “decrease”, “reduce”, or “inhibit” is meant the ability to cause an overall decrease of 50% or greater. In some embodiments, by “decrease”, “reduce”, or “inhibit” is meant the ability to cause an overall decrease of 75%, 85%, 90%, 95%, or greater.
- the amount noted above is inhibited or decreased over a period of time, relative to a control dose (such as a placebo) over the same period of time.
- a “reference” as used herein refers to any sample, standard, or level that is used for comparison purposes.
- a reference may be obtained from a healthy or non-diseased sample.
- a reference is obtained from a non-diseased or non-treated sample of a companion animal.
- a reference is obtained from one or
- SUBSTITUTE SHEET (RULE 26) more healthy animals of a particular species, which are not the animal being tested or treated.
- a reference is an historical and/or population value obtained from a population of healthy animals and does not need to be measured in specific connection with the treatment.
- blood pressure ranges considered normal for various species are generally known and, in some embodiments, are referred to in assessing, e.g., need for treatment, need for prevention, efficacy of treatment, and/or efficacy of prevention.
- substantially reduced denotes a sufficiently high degree of reduction between a numeric value and a reference numeric value such that one of skill in the art would consider the difference between the two values to be of statistical significance within the context of the biological characteristic measured by said values.
- the substantially reduced numeric values is reduced by greater than about any one of 10%, 15% 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, 90%, or 100% compared to the reference value.
- one or more of the methods and/or formulations described herein decrease or substantially decrease a mean arterial blood pressure, a systolic blood pressure, and/or a diastolic blood pressure. In some embodiments, one or more of the methods described and/or formulations herein decrease a mean arterial blood pressure, a systolic blood pressure, and/or a diastolic blood pressure to about, to within about 1 %, to within about 2%, to within about 3%, to within about 4%, to within about 5%, to within about 10%, to within about 15%, or to within about 20% the blood pressure considered normal for the species treated.
- one or more of the methods and/or formulations described herein prevent increase of a mean arterial blood pressure, a systolic blood pressure, and/or a diastolic blood pressure. In some embodiments, one or more of the methods and/or formulations described herein prevent increase of a mean arterial blood pressure, a systolic blood pressure, and/or a diastolic blood pressure to above about, to above about 1 %, to above about 2%, to above about 3%, to above about 4%, to above about 5%, to above about 10%, to above about 15%, or to above about 20% above the blood pressure considered normal for the species treated.
- a canine may be considered to have a normal systolic blood pressure when it is in the range of about 110 to about 160 mm Hg or about 90 to about 140 mm Hg. In some embodiments, a canine may be considered to have a normal diastolic blood pressure when it is in the range of about 60 to about 90 mm Hg or about 50 to about 80 mm Hg. In some embodiments, a canine may be considered to have a normal
- SUBSTITUTE SHEET mean arterial blood pressure when it is in the range of about 60 to about 100 mmHg.
- a feline may be considered to have a normal systolic blood pressure when it is in the range of about 80 to about 140 mm Hg.
- a feline may be considered to have a normal diastolic blood pressure when it is in the range of about 55 to about 75 mm Hg.
- a feline may be considered to have a normal mean arterial blood pressure when it is in the range of about 60 to about 100 mmHg.
- an equine may be considered to have a normal systolic blood pressure when it is in the range of about 105 to about 115 mm Hg. In some embodiments, an equine may be considered to have a normal diastolic blood pressure when it is in the range of about 65 to about 75 mm Hg. In some embodiments, an equine may be considered to have a normal mean arterial blood pressure when it is in the range of about 85 to about 95 mmHg.
- ranges of values set forth herein are intended to operate as a scheme for referring to each separate value falling within the range individually, including but not limited to the endpoints of the ranges, and each separate
- GC stimulator of the S enantiomer of Formula (I) and formulations comprising GC stimulator of the S enantiomer of Formula (I) were generated and evaluated using various procedures as set forth in the following examples.
- GC stimulator of Formula (I) was purified using a high-performance liquid chromatography (HPLC) method.
- HPLC high-performance liquid chromatography
- the physicochemical properties of GC stimulator of Formula (I) and its stability and solubility data were determined by measuring a stirred sample of GC stimulator of Formula (I).
- the stirred sample of GC stimulator of Formula (I) was prepared by stirring the GC stimulator of Formula (I) in toluene at 25°C for seven days.
- the melting point of GC stimulator of Formula (I) was measured by a differential scanning calorimeter (DSC).
- the melting point for both the unstirred and stirred samples of GC stimulator of Formula (I) is 174°C.
- the unstirred sample shows a mass loss measured by thermal gravimetric analysis (TGA) of 0.3 %.
- TGA thermal gravimetric analysis
- the mass loss of the stirred sample is 0.2 %.
- Sample of the GC stimulator of Formula (I) crystalline was stored at 90°C for one week. After storing the GC stimulator of Formula (I) crystalline at 90°C for one week, non-significant degradation was observed. Based on the results of the thermal stability test, it was believed that the GC stimulator of Formula (I) crystalline can be stored at room temperature in a tightly closed container for 6 months.
- the hygroscopicity was determined by measuring a water sorption isotherm at 25°C.
- the GC stimulator of Formula (I) crystalline is not hygroscopic.
- Water uptake is 0.4% at 50% relative humidity (RH)/25°C and 0.7% at 95% RH/25°C.
- UV/VIS radiation stability was determined by exposing the GC stimulator of Formula (I) under a light intensity of 200 Wh/m 2 for 24 hours.
- Samples of solution (10’ 3 mol/l solution of Formula (I) in acetonitrile) and solid forms were placed in 10 mm and 0.5 mm quartz cells, respectively, and exposed to xenon light (Wh/m 2 ).
- Control groups were tested under the same conditions and covered with aluminium foil.
- sample of solution (0.05% of Formula (I) in acetonitrile) was exposed to daylight for 24 hours to simulate the laboratory handling.
- GC stimulator of Formula (I) remained stable when being placed in an aqueous solvent for at least about 1 week under room temperature, or dissolving in an HCI solution of about 0.1 M for at least about 1 week under room temperature, or dissolving in a buffer with a pH value of about 10 for at least about 1 week under room temperature, or dissolving in a phosphate buffer with a pH value of about 7 for at least about 1 week under room temperature, with non-significant hydrolysis observed.
- GC stimulator of Formula (I) crystalline was also tested for its per-oxidative stability.
- Sample of GC stimulator of Formula (I) was placed in aqueous solvent with phosphate buffer adjusting the pH value to 7.
- H2O2 was not added, the GC stimulator of Formula (I) remained stable under room temperature for 24 hours, with nonsignificant hydrolysis observed.
- GC stimulator of Formula (I) was stored under per- oxidative conditions (0.05% Formula (I); 3 % H2O2 in phosphate buffer pH 7; addition of 50 % acetonitrile to improve solubility), a 99.5% degradation was observed after storing the sample under room temperature for 24 hours.
- a Formulation (2) comprising a therapeutically effective amount of a GC stimulator of Formula (I) was prepared.
- Formulation (2) was a suspension and was prepared by mixing the GC stimulator of Formula (I), dibasic sodium phosphate, citric acid, microcrystalline cellulose and carboxymethylcellulose sodium, ethylene oxide/propylene oxide copolymer, sodium hydroxide, hydrochloric acid, and water, in the amount listed in Table 7 below. Specifically, Batches were manufactured at 200 mL scale using a high
- SUBSTITUTE SHEET (RULE 26) shear homogenizer (5 min at 8000 rpm) to activate the microcrystalline cellulose/carboxymethylcellulose sodium, followed by mixing all other ingredients with a stir bar/magnetic plate. Product was filled into 20 mL vials after completion of compounding. Three vials from beginning, middle, and end of filling process were analyzed for content uniformity.
- Comparative Formulation (2) comprising a therapeutically effective amount of a GC stimulator of Formula (I) was also prepared.
- Comparative Formulation (2) was a solution and was prepared by mixing the GC stimulator of Formula (I), dibasic sodium phosphate, citric acid, microcrystalline cellulose and carboxymethylcellulose sodium, ethylene oxide/propylene oxide copolymer, sodium hydroxide, hydrochloric acid, and water, in the amount listed in Table 8 below. Specifically, Batches were manufactured at 200 mL scale using a high shear homogenizer (5 min at 8000 rpm) to activate the microcrystalline cellulose/carboxymethylcellulose sodium, followed by mixing all other ingredients with a stir bar/magnetic plate. Product was filled into 20 mL vials after completion of compounding. Three vials from beginning, middle, and end of filling process were analyzed for content uniformity.
- a Formulation (3) comprising a therapeutically effective amount of a GC stimulator of Formula (I) was prepared.
- Formulation (3) was a suspension and was prepared by mixing the GC stimulator of Formula (I), dibasic sodium phosphate, citric acid, microcrystalline cellulose and carboxymethylcellulose sodium, ethylene oxide/propylene oxide copolymer, sodium hydroxide, hydrochloric acid, and water, in the amount listed in Table 10 below. The mixing process is similar to the process for preparing Formulation (2).
- Comparative Formulation (3) comprising a therapeutically effective amount of a GC stimulator of Formula (I) was also prepared.
- Comparative Formulation (3) was a suspension and included all the ingredients of Formulation (3).
- methylparaben and propylpapaben were added as preservatives to Comparative Formulation (3).
- the methyl and propyl paraben preservative system was selected due to prior art and efficacy at neutral pH.
- the mixing process is similar to the process for preparing Formulation (2).
- a Placebo Formulation (4) without preservatives and a Comparative Placebo Formulation (4) with preservatives were prepared.
- the palatability of the formulations were assessed by observing the uptake of the formulations by cats, and compare that with the uptake of cat milk, with has a high palatability.
- GC stimulator of Formula (I) was not added to either of the formulations to avoid negatively affecting the taste of the formulations.
- the ingredients of the Placebo Formulation (4) and the Comparative Placebo Formulation (4) are listed in Table 12 below, and the results of the palatability study are listed in Table 13 below.
- Placebo Formulation (4) with no preservatives added showed a palatability comparable to the positive control, whereas the Comparative Placebo Formulation (4) with preservatives added showed a significant decrease in palatability.
- a revised Formulation (5) was prepared.
- the ingredients of the Formulation (5) are listed in Table 14 below.
- the objectives for the changes include: (a) increasing concentration of Formula (I) from 0.25% to 1 .0% to reduce dosing volume; (b) changing the citric acid monohydrate:dibasic sodium phosphate ratio to achieve target pH range (pH 6.5 -7.0) without sodium hydroxide/hydrochloric acid adjustment; (c) evaluating different grades and concentrations of microcrystalline cellulose/ carboxymethylcellulose sodium (Avicel CL 611 and Avicel RC 591 ) to improve physical stability of the formulation (reducing sedimentation rate and improving redispersibility); (d) substituting paraben preservatives with n-butyl alcohol due to the parabens’ low solubility (presenting challenges to assessing full dissolution in a suspension product or subsequent precipitation of the material on stability) and poor palatability; and (e) adding vanilla flavor to improve palatability.
- FIG. 1 is a diagram showing the plasma concentration of GC stimulator of Formula (I) after administering Formulation (6) (Table 16) to fasted female European Shorthair Cats, with a dosage of 1 mg/kg of GC stimulator of Formula (I).
- Table 16 Formulation (6)
- Table 17 The parameters are listed in Table 17 below.
- the open squares show the
- SUBSTITUTE SHEET (RULE 26) concentrations for 1/ELC3, the open diamonds show the concentrations for 2/LJR4, and the open triangles show the concentrations for 3/LJY5.
- FIGs. 2 and 3 are diagrams showing the plasma concentration of GC stimulator of Formula (I) after administering oily suspension and aqueous suspension in fed and fasted cats, with a dosage of 1 mg/kg of GC stimulator of Formula (I).
- the PK parameters are listed in Table 18 below.
- the ingredients of the oily suspension formulation (Formulation (7)) used in experiments of FIGs. 2 and 3 are listed in Table 19 of Example 8 below.
- FIG. 2 shows the plasma concentration of Formula I after po administration of 1 mg/kg to fasted and fed female domestic shorthair cats.
- the Y-axis in FIG. 2 is displayed in log scale.
- the squares show the concentrations for fasted cats after administering the aqueous suspension
- the blue circles show the concentrations for fasted cats after administering the oily suspension
- the red circles show the concentrations for fed cats after administering the oily suspension.
- FIG. 3 shows the plasma concentration of Formula I after po administration of 1 mg/kg to fasted and fed female domestic shorthair cats.
- the Y-axis in FIG. 3 is displayed in linear scale.
- the squares show the concentrations for fasted cats after administering the aqueous suspension
- the blue circles show the concentrations for fasted cats after administering the oily suspension
- the red circles show the concentrations for fed cats after administering the oily suspension.
- the PK profile shown in FIGs. 1-3 demonstrate that the GC stimulator of Formula (I), after ingested, can stay in the plasma for a prolonged period.
- the concentration of GC stimulator of Formula (I) can remain over 10 pg/L for 24 hours, or can remain over 10 pg/L for 48 hours, or can remain over 10 pg/L for 60 hours.
- the cats were acclimatized to S Block prior to any dosing for at least 7 days. During the acclimatization period of the study, all cats had undergone a veterinary examination, and were weighed and systolic blood pressure (SBP) measured on at least three occasions.
- SBP systolic blood pressure
- the IVP vehicle placed on at least two occasions to train the cats to accept the liquid via syringe. The acceptance/rejection of the placebo also served as a tool to aid in the selection of the appropriate cats for this study. All cats had a baseline urine and blood sample collected for clinical pathology.
- minor ailments e.g., minor skin lesions, tartar, gingivitis, mild ear or ocular discharge, etc.
- SUBSTITUTE SHEET (RULE 26) investigational veterinary product/test item, hypertensive medication and/or antiinflammatory in the month prior to first treatment were excluded.
- Davs 21 , 28, 35 and 42 pre-treatment and at 2 hours post-treatment for cohort A cats only.
- Days 23, 30, 37 and 44 pre-treatment and at 2 hours post-treatment for cohort B cats only.
- Blood samples for clinical pathology were collected pre-treatment and after the last treatment administration (Day 49) for each cat. Additional samples may be collected if required for investigation of an animal welfare concern.
- Blood samples for determining the plasma pharmacokinetic (PK) profile of the IVP were collected from the treated cats (Groups 1 , 2 and 3) once pre-treatment and at approximately 2, 8 and 24 hours post-treatment on Days 5, 26 and 48, and on Day 51 (approximately 72 hours after the last treatment administration on Day 48).
- a physical examination and blood pressure measurement will be performed. If post-treatment mean SBP measures ⁇ 90mmHg at any point in the study, the cat will be monitored closely, and blood pressure will be measured as required and immediately before the following treatment administration. If the mean SBP has increased to >90mmHg and in the absence of clinical signs, the cat may be treated. If the blood pressure has not increased and/or clinical signs persist the next treatment may be skipped and the following day the cat will return to the previous dose group (e.g., a cat in Group 2 will be dosed as Group 1 , and a cat in Group 3 will be dosed as Group 2).
- the flow chart of Fig. 4 illustrates the blood pressure measurement plan.
- All cats will be treated in a fasted state at approximately the same time each day from Day 0 to Day 48. Dosage will be calculated prior to first treatment according to treatment group allocation (Table 19) and individual body weights determined during acclimation (to an accuracy of 0.1 or 0.01 kg). The calculated dose of the IVP or CP will be rounded up to two decimal points, to the upper closest syringe gradation. IVP dose calculation will be calculated as follows:
- the IVP was prepared and administered to the cats via syringe directly into their mouth.
- the compound was dosed via capsules and if required, the formulation may also be offered on a plate for the cat to consume voluntarily. If a cat vomits after dosing, the cat will not be re-dosed until the next treatment day.
- Feeding of cats influenced the investigated parameters in all study groups (Groups 1 -4 of Table 19). During feeding at approximately 4 hours post treatment with the test item and placebo, blood pressure values and heart rate of cats increased significantly in all study groups. Afterwards, blood pressure as well as heart rate decreased again to levels before feeding.
- Formula (I) at the doses of 0.25 and 0.5mg/kg/day was very well tolerated in healthy normotensive conscious cats under the experimental conditions of the present study.
- Formula (I) at 0.25 and 0.5 mg/kg/day mediated a statistically significant long lasting and dose-dependent decrease in mean, systolic and diastolic blood pressure.
- Plasma protein binding assay was performed to evaluate the binding of Formula (I) to plasma proteins.
- the assay was performed using an equilibrium dialysis method, and a fraction unbound (fu) value was measured.
- the fu value is calculated by the formula below.
- PC Concentration of Formula (I) in protein-containing compartment
- PF Concentration of Formula (I) in protein-free compartment
- Formula (I) stimulated the recombinant sGC concentration dependently from 0.01 to 100 pM with an effect of 1 .3 - to 177- fold.
- the sGC stimulation induced by Formula (I) synergized with 2,2-Diethyl-1-nitroso-oxyhydrazine (DEA/NO) was nearly completely blocked by 1/-/-[1 ,2,4]oxadiazolo-[4,3-a]quinoxalin-1-one (ODQ), and nearly absent in heme-free preparations.
- DEA/NO 2,2-Diethyl-1-nitroso-oxyhydrazine
- Formula (I) has a minimal effective concentration (MEC) at 70 nM and half maximal effective concentration (ECso) at 310 nM.
- Formula (I) reduced coronary perfusion pressure concentration dependently from 1 nM to 10 pM with a maximal effect of about 40% at the highest concentration. Up to the highest concentration, Formula (I) had no effect on heart rate, left ventricular diastolic pressure, and contractility (dP/dt).
- Platelet aggregation (plasma from human donors)
- Formula (I) inhibited ADP (5-10 pM) induced aggregation
- SUBSTITUTE SHEET (RULE 26) also inhibited collagen (3 pg/mL) induced aggregation in platelet rich plasma (ICso 15.6 pM).
- Formula (I) caused an additional and long-lasting decrease in mean arterial blood pressure accompanied by reflex tachycardia.
- the plasma clearance was 4.4 L/(h kg) in rats (moderate to high blood clearance), 1.6 L/(h kg) in dogs (moderate blood clearance) and 0.58 L/(h kg) in monkeys (low blood clearance).
- the volume of distribution was high in all investigated species, with 16 L/kg in rats, 19 L/kg in dogs and 5.5 L/kg in monkeys.
- the terminal elimination half-life of Formula (I) was 2.7 h in rats, 9.2 h in dogs and 7.1 h in monkeys.
- SUBSTITUTE SHEET (RULE 26) absorption is limiting the oral bioavailability, which is in line with high extent of renal excretion of radioactivity after oral compared to iv administration as well as with in vitro data on moderate to high permeability in Caco-2 cells.
- Formula (I) showed a preferential distribution into blood cells in rat, dog, and human (human: Cbiood/Cpiasma ratio 1 .34), whereas in monkey a concentration dependency of the partitioning was observed (0.90 at relevant concentrations in PK studies).
- SUBSTITUTE SHEET (RULE 26) all species resulting from oxidative biotransformation: hydroxylation of the primary amine leading to M-1 , O-debenzylation yielding M-2 (most pronounced in rat) and hydroxylation of the difluorobenzyl moiety. Subsequent further oxidation/conjugation reactions or combinations thereof yielded several secondary metabolites.
- Formula (I) revealed irreversible inhibition ofCYP3A4 with a partition ratio of about 300.
- Formula (I) showed no induction of CYP1A2 and CYP3A4 up to the 6.9 pM in the test system.
- Formula (I) is classified as a permeability glycoprotein (P-gp) substrate with efflux ratios between 10 and 1 at concentrations of 0.1 - 50 pM.
- the efflux was saturable within the concentration range tested.
- SUBSTITUTE SHEET (RULE 26) GLP Behavior (modified Irwin test), Loco-motor activity, Body temperature: rat/WU
- Male rats were assessed for behavioral abnormalities and changes in body temperature at approximately 1 , 3, 6, and 24 h after treatment. At 6 and 24 h after administration, the animals were further tested for potential drug-induced changes in exploratory locomotor activity in an open field. At the low and mid dose level (0.3 and 1 mg/kg), a single oral administration of Formula (I) did not elicit symptoms of substantial behavioral abnormalities in male rats. Except for the occurrence of mushy feces in one of the vehicle-treated animals, the animals displayed normal behavior, both during handling and in the observation cages.
- Formula (I) was associated with increased urination in 2 of 6 animals. Since this effect was seen infrequently and was fully reversible within 24 h, it was regarded not adverse. In the entire dose range tested, a single oral dose of Formula (I) did not interfere with locomotor activity in an open-field, body temperature regulation, and body weight of rats.
- the No Observed Adverse Effect Level (NOAEL) for Formula (I) in rat is 3 mg/kg corresponding to plasma levels (C max ) of 49 pg/L.
- the threshold of hemodynamic effects is 0.15 mg/kg at corresponding plasma levels (Cmax) of 2.6 pg/L. Due to the prominent reflex tachycardia at 1 .5 mg/kg, the NOAEL is regarded to be 0.5 mg/kg.
- Formula (I) was tested in a Salmonella Microsome test for point mutations and in an in vitro and an in vivo micronucleus test for clastogenicity. All tests revealed negative results. Thus, Formula (I) is considered as non-genotoxic.
- Formula (I) was tested in a GLP 2-week repeat-dose study in Wistar rats (10 animals/dose/sex), at daily oral doses of 0, 1 , 3 and 10 mg/kg bodyweight/day.
- MTD maximum tolerated dose
- Formula (I) revealed a toxicological profile in rats which is in line with those known from previous sGC stimulators.
- reduced general condition mainly characterized by clinical findings and reduced body weight gain, was seen starting at 3 mg/kg.
- effects on bone and gastrointestinal tract were seen.
- the effects on RBC parameters and electrolytes as well as on creatinine and urea are seen as secondary to vasodilation and the changes of renal perfusion.
- the NOAEL of the study is 1 mg/kg, based on body weight effects at 3 mg/kg and above.
- SUBSTITUTE SHEET (RULE 26) clinical chemistry, urinalysis) and full post mortem examination including necropsy, organ weight analysis and microscopic examination.
- the concentrations of Formula (I) were determined in plasma samples taken on day 1 and in week 2 at 0.5, 1 , 2, 4, 7, 24 and 48 h after administration respectively.
- SUBSTITUTE SHEET (RULE 26) and 6 females were treated at doses of 0.5 - 1 .5 - 5 mg/kg as satellite animals for toxicokinetic evaluation.
- Formula (I) shows light absorption in the range of 290 to 300 nm. However, in an in vitro 3T3 NRU phototoxicity test it was identified in as a non-phototoxic compound with a photo-irritation factor (PIF) of 1 .7.
- PPF photo-irritation factor
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Chemistry (AREA)
Abstract
L'invention concerne des formulations comprenant un stimulateur de guanylate cyclase (GC). Les formulations peuvent comprendre une suspension orale du stimulateur de GC. L'invention concerne également des méthodes de traitement de l'hypertension et/ou de maladies associées.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263382678P | 2022-11-07 | 2022-11-07 | |
US63/382,678 | 2022-11-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024102699A1 true WO2024102699A1 (fr) | 2024-05-16 |
Family
ID=91033451
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2023/078897 WO2024102699A1 (fr) | 2022-11-07 | 2023-11-07 | Formulations de stimulateur de guanylate cyclase (gc) et leurs utilisations |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024102699A1 (fr) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8198449B2 (en) * | 2008-09-11 | 2012-06-12 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US9126998B2 (en) * | 2012-11-05 | 2015-09-08 | Bayer Pharma AG | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use |
US20150274719A1 (en) * | 2012-11-05 | 2015-10-01 | Bayer Pharma Aktiengesellschaft | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use |
US20170101407A1 (en) * | 2014-05-02 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | 6-chlorine-substituted imidazo[1,2-a]pyridine carboxamides and the use thereof as soluble guanylate cyclase stimulators |
-
2023
- 2023-11-07 WO PCT/US2023/078897 patent/WO2024102699A1/fr unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8198449B2 (en) * | 2008-09-11 | 2012-06-12 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US9126998B2 (en) * | 2012-11-05 | 2015-09-08 | Bayer Pharma AG | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use |
US20150274719A1 (en) * | 2012-11-05 | 2015-10-01 | Bayer Pharma Aktiengesellschaft | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use |
US20170101407A1 (en) * | 2014-05-02 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | 6-chlorine-substituted imidazo[1,2-a]pyridine carboxamides and the use thereof as soluble guanylate cyclase stimulators |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11357855B2 (en) | Liquid formulation | |
ES2496144T5 (es) | Formulación de cápsulas de pirfenidona y excipientes farmacéuticamente aceptables | |
ES2563207T3 (es) | Formas polimorfas, cristalinas y en mesofases de 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4H-1,2,4-triazol-3-iltio)acetato de sodio y sus usos | |
CA2682598C (fr) | Procedes d'administration de la tetrahydrobiopterine, compositions associees et procedes de mesure | |
CN108290918A (zh) | 用于治疗胃肠发炎疾病的jak抑制剂化合物的前药 | |
RU2723642C1 (ru) | Соединения метаболита антагониста рецептора ангиотензина ii и ингибитора nep, и способы их получения | |
JP2000256190A (ja) | 甲状腺類似の抗肥満薬 | |
ES2839248T5 (es) | Estimuladores y/o activadores de la guanilatociclasa soluble (sGC) en combinación con un inhibidor de la endopeptidasa neutra (inhibidor de NEP) y/o un antagonista de angiotensina AII y su uso | |
US11931342B2 (en) | Magnesium biotinate compositions and methods of use | |
TWI519531B (zh) | 阿齊沙坦有機胺鹽及其製備方法和用途 | |
US20200376004A1 (en) | Amorphous onapristone compositions and methods of making the same | |
BRPI0719236A2 (pt) | Composições de carbamato de fenilalquila | |
EP1983973B1 (fr) | Dtpa oral utilisé pour une chélation de radionucléides | |
US20080161279A1 (en) | Methods of Treating Obesity | |
US8124640B2 (en) | Pharmaceutical composition based on idazoxan, salts, hydrates or polymorphs thereof | |
WO2024102699A1 (fr) | Formulations de stimulateur de guanylate cyclase (gc) et leurs utilisations | |
US20090036432A1 (en) | Combinations of AT1-antagonists, amiloride or triamterine, and a diuretic | |
KR20140121383A (ko) | 통풍 환자에서 할로페네이트 또는 할로펜산 및 제 2 요산염-저하제를 사용하여 고요산혈증을 치료하는 방법 | |
US20220054440A1 (en) | Substantially sodium free diclofenac potassium oral solutions | |
EP2162129B1 (fr) | Utilisation d'inhibiteurs de hdac pour le traitement de la destruction osseuse | |
PL209147B1 (pl) | Zastosowanie epotylonów do wytwarzania środka leczniczego do leczenia zespołu rakowiaka i/lub co najmniej jednego guza neuroendokrynnego | |
WO2022199375A1 (fr) | Composition pharmaceutique de composé de quinazoline et son procédé de préparation | |
CA3203125A1 (fr) | Endoxifene pour le traitement du cancer de l'ovaire | |
AU2014240300B2 (en) | Capsule Formulation of Pirfenidone and Pharmaceutically Acceptable Excipients | |
WO2022109198A1 (fr) | Formulations de cystamine et utilisations de celles-ci |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23889576 Country of ref document: EP Kind code of ref document: A1 |